Amino Acid Neurotransmission and its Regulation by Valproate: Focus on Aspartate by Morland, Cecilie
AMINO ACID NEUROTRANSMISSION  
AND ITS REGULATION BY VALPROATE: 
FOCUS ON ASPARTATE 
 
PhD thesis 
 
Cecilie Morland 
 
 
           
Department of Anatomy and Centre for Molecular Biology and Neuroscience 
Institute of Basic Medical Sciences 
University of Oslo, Oslo, Norway 
2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Cecilie Morland, 2012 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 1275 
 
ISBN 978-82-8264-299-6 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AIT Oslo AS.  
 
Produced in co-operation with Unipub.  
The thesis is produced by Unipub merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
3 
 
ACKNOWLEDGMENTS 
Most of the work presented in this thesis was carried out at the Department of Anatomy, 
Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo and the Center 
for Molecular Biology and Neuroscience (CMBN), although some of the studies started at 
the Norwegian Defense Research Establishment (FFI). I am grateful to the University of 
Oslo for providing research facilities and financial support, making this PhD project 
possible, and to FFI for allowing me to use their laboratory facilities whenever needed. 
 
 I would like to thank my supervisor Dr. Vidar Gundersen for sharing his expertise 
with me and for giving me the academic freedom set up my own experiments, yet bringing 
me back to earth when my hypothesis were to far fetched. You have given me invaluable 
guidance and advice, and without you this thesis would not have been possible. 
I would also like to thank the previous head of our laboratory, Prof. Emeritus Jon Storm-
Mathisen for welcoming me to the Synaptic Neurochemistry Laboratory, for sharing his 
knowledge with me and for always looking at things from the positive side. I would like to 
thank the current head of our laboratory, Associate Prof. Linda Hildegard Bergersen, for all 
the effort she has put into creating an encouraging and enthusiastic working environment. 
I am grateful to my co-supervisor, Dr. Bjørnar Hassel, who introduced me to the exciting 
field of neuroscience when I first started as a master student in his lab. Thank you for 
fruitful discussions and for sharing your excellent scientific knowledge, experience and 
enthusiasm! 
 
 To all my current and previous colleagues at the Department of Anatomy who are 
contributing to a nice and inspiring environment: It has been a pleasure working with you! 
A special thank goes to Kaja Nordengen for excellent collaboration during the last year of 
my thesis, and to Maja Puchades for comments on the manuscript. 
4 
 
 I would like to thank all the co-authors: Max Larsson, Aleksander Talgøy Holten, Evy Grini 
Iversen, Kaja Nordengen, Karen A. Boldingh Debernard, Laura M. Prolo and Richard 
Reimer, who have contributed to this work in different ways.  
 A warm thank you goes to my family and friends, who have supported me 
throughout the process of this PhD work. Especially, I would like to thank Bjørn, Christoffer 
and Thomas for being patient and understanding when I have spent long hours in the lab, 
and for reminding me that there are more important things in life than counting gold 
particles…  
 
 
Cecilie Morland 
Oslo, December 2011  
5 
 
CONTENTS 
Acknowledgments ........................................................................................................ 3 
Contents ........................................................................................................................ 5 
List of Publications ......................................................................................................... 7 
Abbreviations ................................................................................................................ 9 
Introduction ................................................................................................................. 11 
The Synapse .................................................................................................................................................. 11 
Cell Types in the Brain ................................................................................................................................... 12 
Excitotoxicity and Glutamate Receptors ....................................................................................................... 13 
Synaptic Glutamate Release ......................................................................................................................... 14 
Glutamate Uptake and the Glutamate-Glutamine Cycle .............................................................................. 15 
The Release Mechanism for Aspartate is Debated ....................................................................................... 17 
Valproate ...................................................................................................................................................... 20 
Valproate as a Tool to Investigate Synaptic Transmission ............................................................................ 21 
Malonate as a Neurotoxin ............................................................................................................................ 22 
Aim of the Studies ........................................................................................................ 23 
Summary of Results ..................................................................................................... 24 
Discussion .................................................................................................................... 27 
Is Aspartate a Neurotransmitter in the Brain? .............................................................................................. 27 
Alternative Release Mechanisms for Aspartate ............................................................................................ 30 
6 
 
Aspartate in Inhibitory Synapses ................................................................................................................... 32 
Valproate ....................................................................................................................................................... 33 
Malonate as a Model for Energy Depletion; Selective Blockage of Neuronal Energy Metabolism ............... 35 
Methodological Considerations ..................................................................................... 37 
Advantages and Disadvantages of Using in vitro Preparations .................................................................... 37 
Synaptic Vesicles............................................................................................................................................ 37 
Antibody Testing ............................................................................................................................................ 38 
Concluding Remarks ..................................................................................................... 39 
References .................................................................................................................... 40 
 
  
 
 
 
7 
 
LIST OF PUBLICATIONS 
This thesis is based on the following original papers: 
 
Paper I    
 
Holten AT*, Morland C*, Nordengen K, and Gundersen V. (2008) Vesicular 
release of L- and D-aspartate from hippocampal nerve terminals: 
immunogold evidence. The Open Neurosci. J.  2:51-58. 
* Holten and Morland contributed equally to the work. 
 
Paper II Morland C, Nordengen K, Larsson MD, Prolo LM, Reimer R, Gundersen V. 
(2011) Vesicular uptake and exocytosis of aspartate is independent of 
sialin. Submitted. 
 
Paper III 
 
Morland C, Nordengen K, Gundersen V. (2011) Valproate causes reduction 
of the excitatory amino acid aspartate in nerve terminals. Under review, 
second round; Neuroscience Letters. 
 
 
Paper IV 
 
Morland C, Boldingh KA, Iversen EG, Hassel B. (2004) Valproate is 
neuroprotective against malonate toxicity in rat striatum: an association 
with augmentation of high-affinity glutamate uptake. J Cereb Blood Flow 
Metab. 24:1226-34. 
  
 
8 
 
Additional papers during the PhD period: 
Bergersen LH, Morland C, Ormel L, Rinholm JE, Larsson M, Wold JFH, Røe ÅT, Stranna A, 
Santello M, Bouvier D, Ottersen OP, Volterra A, Gundersen V. (2011) 
Immunogold detection of L-glutamate and D-serine in small synaptic like microvesicles in 
adult hippocampal astrocytes. Cerebral Cortex.  
 
Larsson M, Sawada K, Morland C, Hiasa M, Ormel L, Moriyama Y and Gundersen V. (2011) 
Functional and anatomical identification of a vesicular transporter mediating neuronal ATP 
release. Cerebral Cortex.  
 
Larsson M, Morland C, Poblete-Naredo I, Biber J, Danbolt NC and Gundersen V. (2011)  
The sodium dependent inorganic phosphate transporter SLC34A1 (NaPi-IIa) is not localized 
in the mouse brain: a case of tissue-specific antigenic cross-reactivity. J. Histochem. 
Cytochem. PMID: 21606201 
 
Nguyen NH, Morland C, Gonzalez SV, Rise F, Storm-Mathisen J, Gundersen V, Hassel B. 
(2007) Propionate increases neuronal histone acetylation, but is metabolized oxidatively by 
glia. Relevance for propionic acidemia. J Neurochem. 101:806-14 
 
Morland C, Henjum S, Iversen EG, Skrede KK, Hassel B. (2007) 
Evidence for a higher glycolytic than oxidative metabolic activity in white matter of rat 
brain. Neurochem Int. PMID: 17316901  
9 
 
ABBREVIATIONS 
AAT Aspartate aminotranferase 
AMPA 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid 
ATP Adenosine triphosphate 
bcl-2 B-cell lymphoma 2 
BKCa Big potassium channels, calcium activated 
BoNT Botulinum toxin  
CNQX  6-Cyano-7-nitroquinoxaline-2,3-dione 
CNS Central nervous system 
CSF Cerebrospinal fluid 
Cx43 Connexin 43 
EAAT  Excitatory amino acid transporter 
GABA  ɶ-amino butyric acid 
GLAST Glutamate aspartate transporter 
GLT Glutamate transporter 
GS Glutamine synthetase 
HSP-70 Heat shock protein, 70kDa 
KB-R7943 2-[2-[4-(4-Nitrobenzyloxy)phenyl]ethyl]isothiourea mesylate 
MCT Monocarboxylate transporter 
MK-801 (5R,10S)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-   
imine hydrogen maleate 
NBQX  2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide 
NMDA N-methyl-D-aspartate 
NPPB 5-Nitro-2-(3-phenylpropylamino)benzoic acid 
PAG Phosphate activated glutaminase 
p-ERK Phosphorylated extracellular signal-regulated kinase 
SDH  Succinate dehydrogenase 
SNAP-25 Synaptosomal-associated protein 25 
SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
SRF Sustained repetitive firing 
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INTRODUCTION 
The Synapse 
By 1850, most biologists recognized cells as the basic unit in living tissue, however there 
was a debate as to whether the “cell theory” also applied to the brain. The existence of the 
nerve cells (neurons) had already been described, but the question of whether nerve fibres 
from different nerve cells were directly connected remained disputed during the late 19th 
century. Camillo Golgi promoted the “reticular theory”, stating that neurons fused at their 
junctions and thereby formed a continuous network, a reticulum. The conflicting theory, 
later known as the “neuron doctrine”, was first expressed by the Norwegian explorer 
Fridtjof Nansen, who argued that neurons were separated by a gap. He recognized the 
contact points between nerve cells as the "principal seat of the nervous activity (...) 
principal seat of intelligence" (Nansen, 1887). However, it was the Spanish neuroanatomist 
Santiago Ramón y Cayal who, during the debate with Golgi, took a leading role in 
defending the “neuron doctrine”. Today we understand that Ramón y Cayal  and Golgi 
were actually discussing the existence of synapses.  
Although the gap between neurons, the synaptic cleft, could not bee seen until the 
invention of the electron microscope in the 1950s, the notion “synapse” was introduced by 
Charles Scott Sherrington in 1906. The same year, Ramón y Cayal  and Golgi shared the 
Nobel Prize in medicine for their work on the anatomy of the nervous system. By that time, 
Ramón y Cayal ’s “neuron doctrine” was accepted by most scientists, although Golgi 
clamed in this Nobel lecture that “this doctrine is generally recognized to be going out of 
favour” (Golgi, 1906).  
Nansen and Ramón y Cayal were right abiout the existence of a gap between the neurons. 
The synapse, consisting of the presynaptic nerve terminal, the postsynaptic element and 
the gap between them, the synaptic cleft, is now known to be fundamental in neuron-to-
neuron signaling. The nature of this signal transmission, however, remained largely 
unresolved until 1921. Then the German pharmacologist, Otto Loewi, performed his 
famous experiments confirming that neurons communicate by releasing chemicals, for 
which he was rewarded the 1936 Nobel Prize in Medicine. Ever since the time of Loewi, 
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indentifying the signaling molecules used by neurons, understanding normal synaptic 
function as well as regulation of synaptic activity in response to usage, stimuli and diseases 
have been a major focus in Neuroscience. The present thesis forms no exception. 
Glutamate has been generally accepted as a neurotransmitter since the 1980s, although 
excitation of neurons by glutamate had been demonstrated electrophysiologically about 
20 years earlier (Curtis and Watkins, 1960). The production of antibodies against amino 
acids (Storm-Mathisen et al., 1983) made it possible to study their location in the brain, 
and was important in establishing glutamate as a signaling molecule, a neurotransmitter, in 
the brain. Later, glutamate was demonstrated to be the main excitatory neurotransmitter 
(for review, see Fonnum, 1984; Ottersen and Storm-Mathisen, 1984b) and the majority of 
neurons use glutamate as their main transmitter. In ĂĚĚŝƚŝŽŶƚŽŐůƵƚĂŵĂƚĞ͕ɶ-amino butyric 
acid (GABA) (Storm-Mathisen et al., 1983) and glycine (Dale et al., 1986) were also 
established as neurotransmitters. Both of these are inhibitory, GABA predominantly in the 
brain and glycine in the spinal cord. 
Here we investigate whether another amino acid, aspartate, can be used as a 
neurotransmitter in central nervous synapses (papers I and II). Aspartergic 
neurotransmission has been debated throughout the last 30-40 years, and will be 
discussed in more details later.  
Synaptic neurotransmission, a highly complex process in the brain, is often altered during 
disease and can be manipulated with neuropharmaca. Papers III and IV of the present 
thesis focus on how the neuro-active amino acids, glutamate, aspartate and GABA, can be 
regulated by an antiepileptic and mood stabilizing drug, valproate. 
  
Cell Types in the Brain 
In addition to neurons, the brain contains ependymal cells and epithelial cells of the 
choroid plexus, cells of the vascular wall (endothelial cells), and glial cells: astrocytes, 
oligodendrocytes, and microglia. The human brain has been estimated to contain ~1011 
neurons (Jessell and Kandel, 1993), and these are classified based on which major 
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neurotransmitter they use. The majority of neurons in the brain are glutamatergic 
(excitatory), and this group might account for up to 80% of all neurons (Ottersen and 
Storm-Mathisen, 1984a). The second largest group of neurons consists of inhibitory, 
GABAergic, neurons. However, both glutamatergic and GABAergic neurons can store and 
release other transmitters as well, from the same nerve terminals (for review, see El 
Mestikawy et al., 2011). The astrocyte/neuron-ratio varies between brain regions, but in 
the human brain, astrocytes outnumber neurons in a 10:1 propotion (Bignami et al., 1991). 
 
Excitotoxicity and Glutamate Receptors 
Glutamate is the predominant excitatory neurotransmitter in the brain (Fonnum, 1984; 
Ottersen and Storm-Mathisen, 1984b), and regulation of glutamate levels is pivotal to 
maintain normal brain function. The presence of glutamate in the extracellular space at 
excessive concentration or for extended periods of time can lead to neuronal death. This 
phenomenon was first discovered in the retina in 1957 (Lucas and Newhouse, 1957), 
although the name ‘‘excitotoxicity’’ was not introduced until later (Olney, 1969). A classic 
model for excitotoxicity is excessive stimulation of the glutamate receptors due to elevated 
extracellular glutamate concentration. The glutamate receptors are primarily localized in 
the postsynaptic membranes or, at lower densities, in the presynaptic membranes and 
extrasynaptically on dendrites and astrocytes. The receptors are divided into two major 
categories; the ionotropic receptors which gate transmembrane ion channels, opening 
them upon binding of the neurotransmitter, and the metabotropic receptors which, upon 
transmitter binding, trigger intracellular signalling cascades. The ionotropic glutamate 
receptors are further divided into three categories according to their ligand selectivity: 2-
amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid (AMPA) receptors, kainate 
receptors, and N-methyl- D-aspartate (NMDA) receptors. All of these are directly linked to 
cation channels. The AMPA and kainate-receptors gate ion channels that are permeable to 
potassium and sodium ions, and are responsible for a fast depolarization of the 
postsynaptic membrane. Some AMPA receptors are also permeable to calcium ions, but 
during development, the Ca2+ permeable subtype of AMPA receptors is replaced by the 
Ca2+ impermeable subtype. Thus, in the adult brain, almost all AMPA receptors are Ca2+ 
impermeable. NMDA receptors, on the other hand, are highly permeable to Ca2+. Due to a 
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voltage sensitive magnesium block of the NMDA-linked ion channel (Mayer et al., 1984; 
Nowak et al., 1984), opening of these channels normally requires that the membrane is 
already depolarized. Thus the NMDA receptors are believed to be responsible for a slower 
response, one that is dependent on parallel activation of other glutamate receptors. 
Although the non-NMDA receptors can contribute to excitotoxicity, the main effect seems 
to be mediated through NMDA receptors (Hahn et al., 1988; Sucher et al., 1991). NMDA 
receptors play a central role in a number of physiological processes, including long-term 
potentiation in the hippocampus (Collingridge et al., 1983; Harris et al., 1984; Morris et al., 
1986; Wigström et al., 1986; Larson and Lynch, 1988) and synaptogenesis (Kitayama et al., 
2003; Manent et al., 2005; Ghiani et al., 2006). However, excessive NMDA receptor 
activation has been implicated in the pathophysiology of both acute incidents like ischemia 
(Arundine and Tymianski, 2004), or severe epilepsy (Ghasemi and Schachter, 2011) and in 
chronic neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, and 
Huntington’s disease (for review, see Kalia et al., 2008). 
 
Synaptic Glutamate Release 
Synaptic vesicles are membrane enclosed organelles, ~40 nm in diameter, that accumulate 
and store neurotransmitters. The vesicular uptake of all known neurotransmitters is driven 
by a vacuolar, ATP consuming, proton pump which generates an electrochemical gradient 
across the vesicular membrane (Maycox et al., 1988). The vesicular glutamate transporters 
(VGLUTs), which are responsible for the uptake of glutamate into synaptic vesicles, use the 
membrane potential established by the proton-ATPase as their driving force. To allow for 
rapid regeneration of releasable neurotransmitter, the synaptic vesicles undergo a tightly 
regulated trafficking cycle. Vesicles that are filled with neurotransmitter dock at the active 
zone, where they undergo priming, making them competent for rapid fusion-pore opening 
upon the arrival of a calcium signal. Glutamatergic neurotransmission is initiated when an 
action potential triggers exocytosis of glutamate-containing synaptic vesicles at the active 
zone of a presynaptic terminal. Exocytosis of synaptic vesicles requires the tightly 
regulated action of SNARE proteins. Synaptic vesicles can endocytose and be recycled by 
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three alternative pathways (Reviewed in Sudhof, 2004); (1) Classic endocytosis via clathrin-
coated pits adjacent to the active zone (Jarousse and Kelly, 2001; Voglmaier and Edwards, 
2007), followed by translocation to the interior of the cell. The vesicles then reacidify and 
refill with neurotransmitters, either directly or after passing through an early endosomal 
intermediate. Alternatively (2), after undocking, the vesicles may be reacidified and refilled 
locally (the “kiss-and-run” model for neurotransmitter release) or finally (3) recently it is 
proposed that the synaptic vesicles can be refilled without undocking from the plasma 
membrane (the “kiss-and-stay” model). The fast pathways, (2) and (3), are preferentially 
used for the rapid recycling of neurotransmitters into the ready releasable pool at low 
stimulation frequencies, while the slower clathrin-dependent pathways, are active at 
higher stimulation frequencies, and recruit the recycling- and reserve pools of synaptic 
vesicles.  
 
Glutamate Uptake and the Glutamate-Glutamine Cycle 
An important defense against excitotoxicity is to keep the extracellular levels of glutamate 
low (at lower μM concentrations). This job is largely done by the excitatory amino acid 
transporters (EAATs). These are high affinity transporters situated in the plasma 
membrane of neurons and astrocytes. They can transport glutamate across the cell 
membranes against a glutamate gradient of several thousand fold (Danbolt, 2001). Five 
such EAATs have been characterized: EAAT1 (GLAST; Storck et al., 1992; Tanaka, 1993), 
EAAT2 (GLT Pines et al., 1992), EAAT3 (EAAC Kanai and Hediger, 1992), EAAT4 (Fairman et 
al., 1995), EAAT5 (Arriza et al., 1997), of which the first three are localized throughout the 
entire brain, EAAT4 is mainly found in the cerebellum, and EAAT5 is exclusively expressed 
in the retina.  
To ensure efficient glutamatergic signalling, it is essential that glutamate levels are kept 
low when no signal is transmitted, i.e. to ensure a high signal/noise response of glutamate 
receptors. Since glutamate is not degraded extracellularly, the glutamatergic signal is 
terminated when the transmitter is taken up into brain cells via the EAATs. Three different 
compartments are involved in the removal of glutamate from the synaptic cleft. Uptake 
into the presynaptic terminal (Gundersen et al., 1993; 1996), probably through EAAT2 
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(Furness et al., 2008), allows glutamate to be taken up into synaptic vesicles (Naito and 
Ueda, 1983), and reused as a neurotransmitter. Another possibility is uptake into the 
postsynaptic dendrite. This is believed to occur through EAAT3 in several brain regions or 
through EAAT4 in the cerebellum. In this case glutamate is lost from neurotransmission, 
but can be used in the energy metabolism. This loss of neurotransmitter must be 
compensated for, otherwise the neurons will be drained of tricarboxylic acid (TCA) cycle 
intermediates (from which glutamate, GABA and aspartate are formed). Anaplerosis, the 
formation of TCA cycle intermediates from substances that are not themselves TCA cycle 
intermediates, may be of importance to maintain energy metabolism and glutamate level 
during neurotransmission (for review, see Hassel, 2000).The bulk glutamate uptake, 
however, is into perisynaptic astrocytes via the astrocytic transporters, EAAT1 or -2, and 
this is the first step of the glutamate-glutamine cycle between neurons and astrocytes 
(figure 1), of which the purpose is recirculation of neurotransmitter glutamate.  Astrocytes, 
but not neurons express glutamine synthetase (GS), an enzyme able to convert glutamate 
to glutamine, and found to be essential for production of releasable glutamate in nerve 
terminals (Laake et al., 1995). From the astrocytes, glutamine is released through system N 
glutamine transporters to the extracellular space (Chaudhry et al., 1999; 2001; Boulland et 
al., 2002; 2003), where it is made available for system A glutamine transporters on the 
neuronal membrane (Jenstad et al., 2009). In the nerve terminal, the mitochondrial 
enzyme, phosphate-activated glutaminase (PAG) converts glutamine into glutamate 
(Kvamme et al., 2008), which can be transported into synaptic vesicles by the VGLUTs and 
thus be ready for synaptic release. 
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Figure 1: Glutamate–glutamine cycle 
VGLUT: vesicular glutamate transporter; EAAT: excitatory amino acid transporter; SN: system N glutamine 
transporter; SAT: system A glutamine transporter; NMDA: N-methyl-D-ĂƐƉĂƌƚĂƚĞ͖DW͗ɲ-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor ; mGluR: metabotropic glutamate receptors; PAG: phosphate-
activated glutaminase; GS: glutamine synthetase. 
 
 
The Release Mechanism for Aspartate is Debated 
The role of aspartate as a classical neurotransmitter in the brain is controversial, since 
direct evidence for synaptic vesicle uptake of aspartate is uncertain. Aspartate was first 
suggested as a neurotransmitter in the hippocampus (Nadler et al., 1976), and later in the 
cerebellum (Wiklund et al., 1982). The general view is that a neurotransmitter must (1) be 
synthesized by the neurons, (2) be taken up into synaptic vesicles and released from the 
nerve terminal by regulated exocytosis. Once released into the synaptic cleft, the 
substance must (3) act on specific receptors to give a postsynaptic response and (4) there 
must be an inactivation system for the substance, to ensure a high signal/noise-ratio. 
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Among neuroactive amino acids, glutamate, GABA, and glycine fulfill these criteria and are 
well established neurotransmitters. 
For aspartate, points 1, 3 and 4 are well established: 
(1) Aspartate can be synthesized in neurons from the TCA cycle intermediate oxaloacetate 
via aspartate aminotransferase (AAT; Altschuler et al., 1985; Kugler, 1987; Martinez-
Rodriguez and Arenas, 1988; Schmidbaur et al., 1990). In this way aspartate can enter the 
“glutamate-glutamine cycle” (Gundersen et al., 1991). (3) Aspartate can excite neurons 
(Curtis et al., 1959), through selective activation of NMDA-type of glutamate receptors 
(Curras and Dingledine, 1992), making aspartate an excitatory amino acid. (4) Termination 
of the aspartergic signal occurs through the EAATs, which transport aspartate and 
glutamate with similar and high affinities from the extracellular space into intracellular 
compartments.  A “low-affinity” uptake system for aspartate and glutamate comprising 
Na+/dicarboxylate transporters has been identified in astrocytes (Holten et al., 2008). 
While the high-affinity transporters work at μM concentrations of aspartate and 
glutamate, the “low-affinity” transporters take up amino acids in the mM range, when the 
EAATs are saturated. 
Whether aspartate is present in synaptic vesicles (point 2), is still an open question. Several 
studies show accumulation of aspartate in nerve terminals, the site where synaptic vesicles 
are located (Merighi et al., 1991; Tracey et al., 1991; van den Pol, 1991; Gundersen et al., 
1998), while others show no evidence for nerve terminal accumulation of aspartate 
(Maxwell et al., 1990; Zhang et al., 1990; Montero, 1994; Larsson et al., 2001). Likewise, 
uptake studies on aspartate in synaptic vesicles have shown conflicting results (Naito and 
Ueda, 1983; Fykse et al., 1992). In the hippocampus, some pathways have been proposed 
to have aspartate-containing vesicles while other pathways show very low aspartate levels.  
The VGLUTs, which are responsible for vesicular storage of glutamate, do not recognize 
aspartate as a transport substrate (Reimer and Edwards, 2004). The lysosomal H+-coupled 
sialic acid transporter, sialin, is located throughout the brain, with especially high levels in 
the hippocampus (Yarovaya et al., 2005), and was suggested to transport aspartate and 
glutamate into synaptic vesicles in the hippocampus (Miyaji et al., 2008). Sialin is regarded 
a promising vesicular aspartate transporter-candidate (Miyaji et al., 2008; for review, see 
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Nadler, 2011), although the role of sialin in release of aspartate from intact nerve terminals 
has not been investigated.  
There are at least four competing hypothesis as to the mechanisms for calcium-dependent 
aspartate depletion from the nerve terminal (figure 2): (a) Aspartate could be released 
from synaptic vesicles through regulated exocytosis during depolarization (in which case, 
aspartate would be classified as a neurotransmitter). Alternatively, (b) during 
depolarization, aspartate might be released through volume- regulated anion channels, 
presumably along with glutamate and other inorganic anions. These anion channels are 
not very well characterized, but several studies show their involvement in accumulation of 
excitatory amino acids in severe cerebral ischemia (Feustel et al., 2004; Zhang et al., 2008). 
(c) Glutamate, but not aspartate, could be released from synaptic vesicles during 
depolarization, and aspartate would then be released through the EAATs, in exchange for 
glutamate, or aspartate could be released through reversed transport by the EAATs during 
depolarization of the nerve terminal membrane. Finally, (d) when glutamate is released 
during depolarization, aspartate could be metabolized by AAT to give glutamate, resulting 
in an apparent loss of aspartate. The evidence for release, however, is massive, thus 
metabolism of aspartate is not likely to be the main contributor to the depletion of 
aspartate from nerve terminals in response to depolarization. The release mechanism for 
aspartate in response to depolarization was addressed in paper I and II of the present  
thesis. 
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

Figure2:Suggestedmechanismsunderlyingthedepletionofaspartatefrom
nerveterminals
a)Aspartateistakenupintovesiclesbyanunknownvesicularexcitatoryaminoacidtransporter(VEAT)and
released through regulated exocytosis. b) Aspartate escapes through the plasma membrane volumeͲ
regulatedanionchannels(VRAC)orc)excitatoryaminoacidtransporters(EAAT,)ord)aspartateisconverted
toglutamateviatheenzymeaspartateaminotransferase(AAT).

Valproate
Valproic acid (2Ͳpropylpentanoic acid) was first
synthesizedin1882(Burton,1882)asanorganicsolvent,
andwasusedtostabilizepossibleanticonvulsantdrugsin
a laboratory test. It soon became evident that valproic
acidhadantiͲseizureactivity (Meunieretal.,1963)and
thefirstclinicaltrialonNaͲvalproateinthetreatmentof

Figure3:Valproicacid
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epilepsy was reported in 1964 (Carraz et al., 1964). Valproate was released as an 
antiepileptic drug three years later and has been used in the treatment of epilepsy since 
then. Today, valproate is very well established and widely used as an antiepileptic agent, 
with a broad spectrum of effects against both generalized and partial seizures in adults and 
children. Later, other indications for valproate-treatment have been established; 
psychiatric disorders, migraine prophylaxis and the management of trigeminal or post-
herpetic neuralgia. Although valproate is one of the most widely used drugs in neurology 
and psychiatry, its mechanism of action is still controversial. A regulatory effect on 
neurotransmission might explain some of the clinical implications for valproate, and is 
discussed below.  
 
Valproate as a Tool to Investigate Synaptic Transmission 
Valproate changes the brain level of aspartate and GABA.   
The classic view is that epileptogenesis is caused by an imbalance between activation and 
inhibition of neurons, resulting from excessive glutamatergic (and possibly aspartergic) 
transmission, deficient GABAergic transmission, or a combination of the two. Accumulation 
of GABA (Godin et al., 1969; Macdonald and Bergey, 1979; Battistin et al., 1984; Löscher 
and Vetter, 1984a; Löscher and Vetter, 1984b; Löscher and Hörstermann, 1994) in the 
brain after valproate treatment is well established, and probably contributes to it´s 
anticonvulsant effect. In addition, valproate causes the brain levels of aspartate to 
decrease (Kukino and Deguchi, 1977; Schechter et al., 1978), without affecting the 
concentration of glutamate (Johannessen et al., 2001). The increase in GABA levels appears 
to be specific for the nerve terminals (Iadarola and Gale, 1979; Löscher and Vetter, 1985). 
The effect of valproate on the distribution of aspartate between different subcellular 
compartments remains unknown. If aspartate is predominantly reduced in the nerve 
terminals compared to, for instance, the somato-dendritic compartments, this would 
reflect reduced excitatory signaling and point to an additional mechanism for the 
anticonvulsive action of valproate. This hypothesis was tested in paper IV. 
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Valproate and regulation of EAATs 
As mentioned above, the EAATs are important for keeping the extracellular glutamate 
concentration at a low level. In spite of its critical importance in pathology and normal 
synaptic transmission, the regulation of EAATs is poorly understood. In addition to the 
effects of valproate on neurotransmission, valproate is a well established histone 
deacetylase inhibitor, having the potential to increase gene expression (Phiel et al., 2001). 
Whether valproate could regulate the expression of proteins involved in transmitter 
signaling in the brain is largely unknown. Long-term (90 days) treatment with valproate 
was, however, in a previous study shown to give increased levels of EAAT2 in the 
hippocampus (Hassel et al., 2001). In paper IV we investigate the effect of shorter 
valproate treatment (2 weeks) on the EAAT2 level, glutamate uptake, and neuroprotection 
against excitotoxicity. 
 
Malonate as a Neurotoxin 
Malonate is a competitive inhibitor of succinate dehydrogenase (SDH), the enzyme that 
converts succinate to fumarate in the TCA cycle, and inhibition of SDH results in loss of ATP 
in the cells (Erecinska and Nelson, 1994). Malonate-induced neurotoxicity is largely 
excitotoxic, as these lesions can be prevented by glutamate receptor antagonists (Beal et 
al., 1993; Greene and Greenamyre, 1995; Ikonomidou et al., 2000). In the present work, 
malonate was used as a neurotoxin, to generate a lesion in rat striatum after intrastriatal 
injection. We demonstrate that malonate inhibit neuronal metabolism, yet leave the 
astrocytes capable of glutamate uptake, indicating that malonate toxicity is neuron 
specific. 
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AIM OF THE STUDIES 
Determine the release mechanisms for aspartate from nerve terminals 
 
Clarify regulatory effects of valproate on aspartergic neurotransmission 
 
Explore the neuroprotective effect of valproate in malonate-toxicity  
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SUMMARY OF RESULTS 
Paper I 
Vesicular Release of L- and D-Aspartate from Hippocampal Nerve Terminals: 
Immunogold Evidence 
To investigate whether release through EAATs was important for aspartate depletion from 
nerve terminals in response to depolarization, we exposed rat hippocampal slices to 
normal (3 mM) and depolarizing (55 mM) concentrations of K+, with or without the EAAT 
inhibitor, threo-beta-benzyloxyaspartate (TBOA). By light- and electron microscopy 
analysis, we showed that the majority of aspartate depletion was EAAT-independent and 
that only a small fraction of aspartate depletion from hippocampal nerve terminals during 
K+-induced depolarization could be blocked by TBOA. A similar release pattern was 
observed for the well established excitatory neurotransmitter glutamate. While L-
aspartate is present at μM concentrations in the brain, endogenous D-aspartate is at trace 
levels. When hippocampal slices were exposed to exogenous D-aspartate before 
immersion-fixation of the tissue, immunogold cytochemistry showed D-aspartate uptake in 
terminals, where immunostaining was concentrated over synaptic vesicles as opposed to 
the cytoplasmic matrix. Together, these data suggest a vesicular localization of aspartate 
and release of aspartate through an EAAT-independent mechanism, probably exocytosis. 
 
Paper II 
Vesicular uptake and exocytosis of aspartate is independent of sialin 
The release mechanism for aspartate has been debated for years, as there has been 
discrepancy between studies of vesicular aspartate uptake. We show that isolated synaptic 
vesicles were capable of accumulating aspartate, and that the vesicular uptake of 
radiolabeled aspartate (relative to the uptake of glutamate) varied between brain regions. 
The highest uptake of aspartate (18% of the uptake of glutamate) was found in the 
hippocampus, while the entorhinal cortex, the frontal cortex and the striatum showed 
uptakes of 9.6%, 10% and 12%, respectively, similar to what we observed in whole-brain 
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vesicles (9%). Although we demonstrate vesicular accumulation of aspartate, our results 
suggest that the vesicular aspartate transporter remain unidentified. Sialin has been 
suggested to transport aspartate and glutamate into hippocampal vesicles (Miyaji et al., 
2008), but here we demonstrate that release of aspartate from nerve terminals was 
independent of sialin. Sialin knock-out mice and wild-types showed the same ability to 
deplete aspartate from the nerve terminals in response to depolarization. We further 
investigated the importance of two suggested non-vesicular release mechanism for 
aspartate; volume-regulated anion channels (VRACs) and excitatory amino acid 
transporters (EAATs), but found no evidence for release through these mechanisms. We 
confirmed that the depletion of aspartate from nerve terminals was strictly calcium 
dependent, as it could be completely inhibited by replacing extracellular calcium with 
magnesium. Furthermore, KB-R7943, which inhibits calcium influx both through the 
reversed Na+/Ca2+ exchanger, transient receptor potential channels, and NMDA receptors 
(Sobolevsky and Khodorov, 1999; Arakawa et al., 2000), inhibited both aspartate and 
glutamate depletion. We conclude that aspartate is accumulated in synaptic vesicles and 
released through exocytosis after vesicular accumulation by a yet unidentified transporter. 
 
Paper III 
Valproate causes reduction of the excitatory amino acid aspartate in nerve 
terminals 
The antiepileptic and mood stabilizing drug, valproate, causes the brain level of the 
excitatory transmitter aspartate to decrease. The effect of valproate on the distribution of 
aspartate between different subcellular neuronal compartments, however, remains 
unknown. Here we show that valproate treatment caused decreased aspartate levels in 
both excitatory and inhibitory nerve terminals. The decrease occurred selectively in nerve 
terminals, as the aspartate level in stem dendrites was largely unchanged. Glutamate and 
GABA in excitatory and inhibitory nerve terminals, respectively, showed only minor 
changes after valproate treatment. The most pronounced effect, thus, was that on 
aspartate; A 64% reduction in excitatory terminals and a 62% reduction in inhibitory 
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terminals. Our data point to a potentially important clinical mechanism for valproate; 
reduced aspartergic neurotransmission. 
 
 Paper IV 
Valproate is neuroprotective against malonate toxicity in rat striatum: an 
association with augmentation of high-affinity glutamate uptake 
Valproate has neuroprotective properties, and several mechanisms have been proposed to 
underlie this effect. We treated rats with valproate for 14 days (300 mg/kg twice daily) 
before malonate (1.5 μmol; 1 M) was injected into their right striatum. We found that 
valproate-treated animals developed smaller lesions  than control animals in response to 
malonate toxicity. The lesions were due to malonate toxicity and not hyperosmolarity, 
since injection of NaCl that was equiosmolar with 1 M malonate, caused lesions that were 
about 20 times smaller than the lesions caused by malonate. Injection of physiologic saline 
did not cause lesions. By microdialysis, we showed that valproate pre-treatment of rats 
reduced extracellular accumulation of glutamate and aspartate in response to malonate 
toxicity in the striatum. This effect paralleled an increase in the striatal level of the 
excitatory amino acid transporter EAAT2, and an augmentation of high-affinity glutamate 
uptake into striatal proteoliposomes. Malonate injection caused a reduction in striatal 
adenosine triphosphate (ATP) content, however our data indicate that malonate did not 
inhibit the glial ATP production, which is necessary for uptake of glutamate. Western blot 
analysis showed that the striatal levels of HSP-70 and fos were reduced, and the levels of 
bcl-2 and phosphorylated extracellular signal-regulated kinase (p-ERK) remained 
unaffected. Histone acetylation was increased by valproate treatment. The results 
suggested that augmentation of excitatory amino acid uptake was an important 
contributor to valproate-mediated neuroprotection in the striatum. The results further 
suggest that increased uptake of excitatory amino acids from the extracellular fluid may be 
a mechanism of action of valproate as an antiepileptic drug. 
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DISCUSSION 
Is Aspartate a Neurotransmitter in the Brain? 
Aspartate fulfills most criteria normally required to be classified as a neurotransmitter, but 
the release mechanism of aspartate has been debated for 30-40 years and still remains 
unresolved. The major point of discussion has been whether aspartate is packed into 
synaptic vesicles and released from nerve terminals by exocytosis, or if the release occurs 
primarily through plasma membrane transporter(s) or channel(s).  
Immunostaining for aspartate is found in the nerve terminals, where it is higher over 
synaptic vesicles than over the cytoplasmic matrix (Gundersen et al., 1998). These data 
clearly demonstrate the presence of aspartate in the terminals, and suggest accumulation 
of aspartate in synaptic vesicles, however, they are not conclusive. Theoretically, during 
the fixation process, amino acids in close proximity to protein rich organelles, like synaptic 
vesicles, have a better chance of being fixed in the tissue than amino acids in less protein-
rich areas, like the cytosol. However, while the putative neurotransmitters glutamate and 
aspartate showed significant association with synaptic vesicles, the labeling for the non-
transmitter amino acids glutamine and taurine, was equally distributed between the 
vesicle clusters and the cytoplasmic matrix (Gundersen et al., 1998). Thus, intra-vesicular 
localization of aspartate is likely, but binding of cytosolic aspartate to the vesicular surface 
could also explain the association of aspartate with synaptic vesicles. These arguments also 
apply to the accumulation of exogenous D-aspartate reported in paper I.    
In paper II, we show that aspartate is taken up into synaptic vesicles. This has been an 
open question until now, as some studies have demonstrated vesicular uptake and 
localization of aspartate (Naito and Ueda, 1983; Fleck et al., 2001; D'Aniello et al., 2011) 
while others have found vesicular accumulation of aspartate to be negligible (Maycox et 
al., 1988; Fykse et al., 1992). This discrepancy is not easily understood, as authors have 
used similar methods, but arrives at highly different answers (see for instance Naito and 
Ueda, 1983; Fykse et al., 1992). Both D’Aniello and co-workers (2011) and Fleck and co-
workers (2001) found that aspartate levels in synaptic vesicles were similar to glutamate 
levels, however the former group detected a higher level of aspartate in whole brain 
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homogenate (aspartate:glutamate ratio = 0.8) than reported by most other authors (a ratio 
of 0.2-0.3; Paper IV; Liebschutz et al., 1977; Fonnum et al., 1981; Alvestad et al., 2008; 
Kokras et al., 2009). The latter study did not exclude the possibility for enzymatic 
conversion of [3H]L-aspartate (and possibly [3H]D-aspartate, via D-aspartate racemase or 
D-aspartate oxidase) to [3H]-glutamate in the synaptosomes prior to vesicular uptake.  
The aspartate uptake reported in paper II, 9.1% (of the glutamate uptake), is lower than 
indicated by the studies of D’Aniello et al. (2011) and Fleck et al. (2001), but consistent 
with the value obtained by Naito and Ueda (1983). Our experiments eliminate the 
possibility of unspecific temperature-dependent binding to the vesicles, as our negative 
controls (the radioactivity of which were subtracted from the radioactivity measured in the 
samples, to calculate the actual uptake) were treated identically to the samples, except 
that ATP was omitted from the negatives. Thus, we measure only the ATP dependent 
uptake of aspartate in the vesicles. 
The principal step in vesicular release, fusion with the plasma membrane, is triggered by a 
rise in intracellular calcium, and experiments with different brain preparations from 
different brain regions show that the release of aspartate in response to depolarization is 
highly calcium -dependent (Girault et al., 1986; Burke and Nadler, 1988; Szerb, 1988; 
Paulsen and Fonnum, 1989; Gundersen et al., 1991; Roisin et al., 1991; Fleck et al., 1993; 
Zhou et al., 1995; Gundersen et al., 1998; Bradford and Nadler, 2004; Zappettini et al., 
2010), although some studies failed to demonstrate calcium dependency of the aspartate 
release (Levi et al., 1982; Wilkinson and Nicholls, 1989; McMahon and Nicholls, 1990). The 
depletion of aspartate described in this thesis is strictly dependent on extracellular 
calcium, as reducing calcium in the incubation medium to 0.1 mM (magnesium elevated to 
10 mM) totally prevented aspartate depletion in response to depolarization (paper II). The 
demonstration of calcium dependent release is an indicative, but not conclusive, 
confirmation of exocytosis.  
The action of soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) proteins are essential for exocytotic release of neurotransmitters, and 
dependency of SNARE proteins is generally regarded as a definite test for exocytosis. 
Clostridal bacteria synthesize a series of neurotoxins that inhibit priming of synaptic 
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vesicles during the process of exocytosis; tetanus toxin (TTX) and botulinum toxins (BoNT) 
B, D, F, G and H which cleave the vesicular SNARE synaptobrevin, BoNT/A and E, which 
specifically cleave SNAP-25, and BoNT/C, which cleave both SNAP-25 and syntaxin. Studies 
on the effect of botulinum and tetanus toxin on aspartate release show conflicting results, 
as sensitivity towards clostridal toxins has been demonstrated in hippocampal slices 
(Gundersen et al., 1991; 1998) and some studies on synaptosomes (McMahon et al., 1992; 
Wang and Nadler, 2007; Cavallero et al., 2009), but not in another (Bradford and Nadler, 
2004). Clostridal toxins, consist of a light chain and a heavy chain. Cleavage of the SNARE 
proteins by these toxins, is dependent on internalization of the proteolytic light chain. This 
occurs through endocytosis during vesicle recycling, and requires binding of the heavy 
chain to vesicular proteins expressed on the plasma membrane. Some researchers believe 
that the release of aspartate occurs through exocytosis of vesicles at ectopic locations (for 
discussion, see Nadler, 2011). As vesicle recycling, and thus the internalization of clostridal 
toxins mainly takes place near the active zone, the intracellular concentration of the toxins 
are likely to be highest in this area. Thus, the concentration of the toxin at the locations for 
aspartate release might not be high enough to inhibit exocytosis. Although some 
conflicting results exist regarding the sensitivity or aspartate release to clostridal toxins, 
most release data point to a clostridium toxin-sensitive, most likely vesicular, release 
mechanism for aspartate.  
The major objection to the concept of aspartergic vesicular release is that no vesicular 
aspartate transporter has been identified. The lysosomal H+-coupled sialic acid transporter, 
sialin, was suggested to transport aspartate and glutamate into synaptic vesicles in the 
hippocampus (Miyaji et al., 2008). Sialin is located throughout the brain, with especially 
high levels in the hippocampus (Yarovaya et al., 2005) and has been regarded a vesicular 
aspartate transporter-candidate (Miyaji et al., 2008; for review, see Nadler, 2011), even 
though the role of sialin in release of aspartate from intact nerve terminals has not been 
investigated. In paper II we show that aspartate labeling under basal conditions and 
aspartate depletion from nerve terminals in response to depolarization is equal in slices 
from sialin knock-out mice and controls, indicating that sialin is not important for vesicular 
accumulation and release of aspartate. These results suggest that sialin is either not 
present in sufficient amounts in the vesicular membrane, or that sialin does not transport 
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aspartate under physiological conditions. In the study by Miyaji and co-workers (2008), the 
authors report to have detected sialin in the hippocampal P2 fraction. According to 
standard nomenclature, the P2 fraction refers to a crude synaptosome fraction (see for 
instance Kadota and Kadota, 1973; Huttner et al., 1983), which contains mitochondria and 
probably lysosomal membranes. Thus, the localization of sialin in synaptic vesicles is still 
uncertain. The assumption that sialin is not a constituent of synaptic vesicles is supported 
by Takamori and co-workers (2006) who did not detect sialin in a proteomics study of 
synaptic vesicles. According to Miyaji and co-workers (2008), the affinity of sialin is similar 
for aspartate and glutamate, and higher than the affinity of the VGLUTs for glutamate. In 
neurons, the intracellular concentration of aspartate is about 1:5 of the glutamate 
concentration (Nadler et al., 1976). If sialin was present in sufficient amounts to be 
important for vesicular aspartate accumulation, it would probably also be important for 
the uptake of glutamate. This is contradicted by data from VGLUT knock-out animals 
(Fremeau, Jr. et al., 2004). Altogether, the evidence suggests that sialin is not important for 
the uptake and release of aspartate from nerve terminals. 
 
Alternative Release Mechanisms for Aspartate 
Reversal of EAATs (Szatkowski et al., 1990) has been confirmed a major contributor to the 
high extracellular levels of EAAs, including aspartate, in severe brain ischemia (Phillis et al., 
1998; Seki et al., 1999). However, in our hippocampal slices we show that the EAATs are 
not a major release mechanism for aspartate during neuronal membrane depolarization 
(papers I and II), since inhibition of EAATs with TBOA did not prevent depletion of 
aspartate.  
Release of aspartate and glutamate through volume-regulated anion channels (VRAC) has 
been shown to be an important contributor to extracellular accumulation of these 
excitatory amino acids in ischemia (Feustel et al., 2004; Zhang et al., 2008) and spreading 
depression  (Basarsky et al., 1999). As in vivo studies do not differentiate between amino 
acids released from neurons and astrocytes, the cellular origin of the excess excitatory 
amino acids during these pathological conditions is not known, although the effect of VRAC 
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inhibition on release of EAAs has been confirmed in cultured astrocytes (Rutledge et al., 
1998). The molecular identity of VRAC is unknown (for discussion, see Eggermont et al., 
2001; Hoffmann et al., 2009), and it is not known whether the concept of VRAC refers to 
one single channel or to a whole family of related anion channels. Consequently, 
antibodies against these channels have not been developed and the localization of these 
channels can only be based on physiological experiments. Our data indicate that in 
neurons, at least in the presynaptic terminals, VRACs are not a major release mechanism 
for neither aspartate nor glutamate, as inhibition of VRAC by NPPB, did not alter the 
content of these amino acids in synaptic terminals. The concentration of NPPB used in this 
study (100μM) has been shown to almost completely inhibit VRAC-mediated Cl--currents 
(Sagheddu et al., 2010; Zhang et al., 2011). Our findings are consistent with studies 
demonstrating that, while astrocytes are likely to undergo rapid volume regulation through 
swelling in response to acute pathological states (Van Harreveld, 1966; Kimelberg et al., 
2000; Mongin and Kimelberg, 2005; Risher et al., 2009), neuronal volumes (Andrew et al., 
2007) appear resistant to changes in external osmolarity. The neuronal volume stability 
and lack of fast volume regulation is likely due to the lack of aquaporins on the neuronal 
plasma membrane, giving neuronal membranes low water permeability. Whether neurons 
express VRAC is not known (but see Zhang et al., 2011). 
 
It should be mentioned that NPPB inhibits connexin Cx43 (Ye et al., 2009) and 
monocarboxylate transporters (MCTs) (Carpenter and Halestrap, 1994; Rinholm et al., 
2011), at the same concentrations that block VRAC. Cx43 is primarily expressed on 
astrocytes, where it exists in half of a gap junction (hemichannel) (Bennett et al., 2003; Ye 
et al., 2003; Spray et al., 2006) that are capable of releasing molecules less than 1kD, 
including amino acids. To my knowledge, the localization of connexins in the nerve 
terminal membranes has not been reported, and the inhibitory effect of NPPB on Cx43 is 
therefore not likely to affect the nerve terminal content of aspartate and glutamate 
directly. Since the MCTs do not transport amino acids, and have not been reported as 
constituents of the plasma membrane of nerve terminals, a direct effect of MCT inhibition 
on release of aspartate and glutamate is not likely. However, inhibition of mitochondrial 
MCTs (Butz et al., 2004; Hashimoto et al., 2008), which transport pyruvate and lactate 
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across the inner mitochondrial membrane, would lead to functional hypoglycemia and 
subsequently to increased aspartate levels (Gundersen et al., 1998). In parallel analyses we 
demonstrate that aspartate accumulates in astrocytes in response to NPPB exposure (data 
not shown), while the aspartate level in nerve terminals (paper II) is unchanged. This 
finding suggests a selective action of NPPB on astrocytes.  
Taken together, our data (paper I and II) do not support the notion of VRACs and EAATs as 
important release mechanisms for aspartate from nerve terminals under physiological 
conditions, leaving exocytosis as the most likely release mechanism. 
 
Aspartate in Inhibitory Synapses 
Both in perfusion-fixed rat hippocampus and in mouse and rat brain slices, the labeling 
density of aspartate in inhibitory terminals was approximately twice that in excitatory 
terminals (papers II and III). This is in agreement with several studies showing higher 
aspartate levels in GABAergic neurons than in glutamatergic neurons (Storm-Mathisen et 
al., 1986; Hassel et al., 1995; Gundersen et al., 2001a) and probably has a metabolic 
explanation: The rate-limiting enzymes of the oxidative metabolism are pyruvate 
ĚĞŚǇĚƌŽŐĞŶĂƐĞĂŶĚɲ-ketoglutarate dehydrogenase (Lai et al., 1977; Morland et al., 2007). 
In GABAergic neurons the GABA-ƐŚƵŶƚ;&ŝŐƵƌĞϰͿĐĂŶĐŝƌĐƵŵǀĞŶƚƚŚĞƐƚĞƉĐĂƚĂůǇǌĞĚďǇɲ-
ketoglutarate, facilitating the flux through to oxaloacetate. The conversion of oxaloacetate 
to citrate, however, is dependent of acetyl-CoA formed by pyruvate dehydrogenase. Thus 
oxaloacetate, and subsequently aspartate, accumulates in these neurons. What the 
physiological functions of aspartate release from inhibitory terminals might be, is an 
intriguing question. At GABAergic synapses, aspartate is probably the main agonist acting 
on the NMDA-receptors, which have been found at high densities along the post-synaptic 
membranes of these synapses (Gundersen et al., 2004).  
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Figure 4: TCA cyclewith the GABA shunt 
TCA cycle (black) and GABA shunt (blue). The rate limiting enzymes are in red 
 
Valproate  
Dosage and Route of Administration 
Valproic acid is almost fully dissociated at physiological pH, giving it a high water solubility 
and a low volume of distribution compared to most anticonvulsant drugs (Löscher and 
Frey, 1984). A steady-state situation, where the concentration of valproate in 
cerebrospinal fluid (CSF) equals about 20 % of the serum concentration, is rapidly reached, 
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as the valproate level in brain and CSF peak at approximately the same time as the plasma 
concentration (Löscher and Esenwein, 1978). This predictable access of valproate to the 
brain justifies systemic administration of valproate, as used in this thesis. The elimination 
of valproate is mainly through biotransformation (reviewed in Baillie and Sheffels, 1995). 
While the half-life of valproate in humans is reported as 9-18 hours, the degradation in rats 
is much faster (elimination half-life of 2-5; non-linear kinetics; Löscher, 1999). This explains 
why higher doses of valproate are required in rats to obtain plasma concentrations within 
the therapeutic window used for humans. The dose used in this thesis, 300mg/kg, twice 
daily, is within the range use in other in vivo studies (Kukino and Deguchi, 1977; Chapman 
et al., 1982; Löscher and Hörstermann, 1994; Hassel et al., 2001; Johannessen et al., 2001)  
 
Valproate and Brain Energy Metabolism: Effects on GABA and Aspartate 
Because of the wide spectrum of actions against different types of seizures and neuro-
psychiatric disorders, valproate is suggested to act by a combination of different 
mechanisms.  
A bulk increase in GABA (Godin et al., 1969) accompanied by a reduction in aspartate 
(Chapman et al., 1982; Löscher and Hörstermann, 1994) has been suggested as an 
important anti-epileptic mechanism for valproate. The increase in GABA is believed to 
occur predominantly in inhibitory nerve terminals (Iadarola and Gale, 1979; Löscher and 
Vetter, 1985). In paper II, we show that the decrease in aspartate occurs selectively in 
nerve terminals. In excitatory nerve terminals, only aspartate and not glutamate, was 
significantly reduced by valproate treatment. This is in line with biochemical studies 
showing that valproate selectively inhibits the release of aspartate in preference to 
glutamate (Crowder and Bradford, 1987; Biggs et al., 1992). Similarly, in inhibitory 
terminals, the decrease in aspartate was much more pronounced than the increase in 
GABA. sĂůƉƌŽĂƚĞ ŝŶŚŝďŝƚƐ ƚŚĞ ŝŶƚƌĂŵŝƚŽĐŚŽŶĚƌŝĂů ĞŶǌǇŵĞ ɲ-ketoglutarate dehydrogenase 
(Johannessen et al., 2001), which leads to reduced concentration of oxaloacetate and, 
thereby of aspartate, which is formed from oxaloacetate via the aspartate 
aminotransferase reaction. The selective effect in nerve terminals might be due to a higher 
turnover of transmitter amino acids in nerve terminals than in somato-dendritic 
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compartments (Hassel et al., 1997). Reduced aspartergic neurotransmission might be an 
additional antiepileptic effect of valproate.  
 
Inhibiton of voltage-gated sodium channels? 
Another proposed mechanism of action for valproate is inhibition of sustained repetitive 
firing (SRF) of neurons, due to inhibition of voltage-gated sodium channels (Slater and 
Johnston, 1978; McLean and Macdonald, 1986; Vreugdenhil et al., 1998) or enhancement 
of potassium channel function involved in action potential repolarization (Morre et al., 
1984; Franceschetti et al., 1986). However, a direct effect of valproate on voltage-gated 
sodium channels has been questioned (Löscher, 1993; Albus and Williamson, 1998), and 
the effect on potassium channels has only been demonstrated at supra therapeutically 
doses of valproate. Consequently, inhibition of SRF is has been disregarded as a clinically 
important mechanism of action (Löscher, 1999; Johannessen et al., 2001), further 
underscoring the importance of discovering other mechanisms of action, as for instance 
that of aspartate as discussed above.  
 
Malonate as a Model for Energy Depletion; Selective Blockage of 
Neuronal Energy Metabolism  
Malonate is a competitive inhibitor of succinate dehydrogenase (SDH), a key enzyme in 
both the tricarboxylic acid (TCA) cycle and the oxidative phosphorylation, and thus 
inhibition of SDH results in loss of ATP in the cells (Erecinska and Nelson, 1994). The brain 
lesions caused by injection of malonate can be prevented by glutamate receptor 
antagonists  (Beal et al., 1993; Greene and Greenamyre, 1995; Ikonomidou et al., 2000), 
indicating that excitotoxicity is a key mechanism. Inhibition of neuronal metabolism 
impairs the neurons’ ability to maintain resting membrane potential. The resultant 
depolarization may relieve the voltage-dependent magnesium block of the NMDA 
receptor, allowing for easier receptor activation and greater flux through the receptor’s ion 
channel. The resultant excessive inward flux of predominantly Ca2+, but also Na+, might 
lead to neuronal death. Thus, excitotoxicity after metabolic inhibition seems to be mainly 
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through excessive NMDA-receptor activation, thus the increase in extracellular glutamate 
that we and others (Messam et al., 1995) find after intrastriatal malonate injection is likely 
to play an important role for the neurotoxicity of malonate. 
To understand how valproate can be neuroprotective against malonate toxicity, selectivity 
of malonate action on neurons over astrocytes is an important aspect. Several findings 
suggest that malonate inhibits the energy metabolism in neurons but not in astrocytes: 
First of all, malonate is selectively taken up into neurons, as the specific activity of 
glutamate is higher that that of glutamine after injection of radiolabeled malonate 
(Koeppen et al., 1978; Mitzen and Koeppen, 1984; Hassel et al., 2002). Second, malonate 
toxicity is characterized by inhibition of glutamate synthesis from (radiolabeled) glucose 
(Paper IV), a predominantly neuronal reaction (Storm-Mathisen et al., 1983; Hassel et al., 
1997). Third, ATP-dependent formation of glutamine from radiolabeled glucose (e.g. 
Powers and Riordan, 1975), a strictly glial reaction in the brain (Martinez-Hernandez et al., 
1977), was not reduced in response to malonate poisoning. Radiolabeled glutamate 
injected into malonate-treated striatum was converted to glutamine (paper IV), strongly 
suggesting that the astrocytes were capable of glutamate uptake and glutamine synthetase 
activity, two ATP dependent processes, even in the presences of malonate. Together these 
findings indicate that, although neuronal energy metabolism was inhibited, astrocytes 
could generate energy to support glutamate transport during malonate exposure. Thus, 
the valproate-induced increase in EAAT2 (paper IV) most probably led to increased 
glutamate uptake into astrocytes in vivo and reduced excitotoxic stress on the neurons, 
and therefore contribute to the neuroprotective effect.    
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METHODOLOGICAL CONSIDERATIONS 
Advantages and Disadvantages of Using in vitro Preparations 
In this thesis I have used some in vitro models: hippocampal slices, isolated synaptic 
vesicles and proteoliposomes. In vitro models are suitable for studies of detailed molecular 
mechanisms, which are not easily investigated in whole animals. In vitro preparations can 
easily be manipulated with, without the ethical consideration of animal welfare, which is 
necessary when doing in vivo experiments. Thus, they can be invaluable models and 
replacements for in vivo studies. Although in vitro models in many cases are important test 
systems, extrapolation to the in vivo situation should always be done with caution. 
Differences between in vitro and in vivo results can reflect for instance endocrine- or 
paracrine factors, immune responses, direct communication with other cells, and 
availability of nutrients and oxygen. 
For papers I and II we used hippocampal slice preparation as an in vitro model for 
hippocampal function. The main advantage with this model is that one can study the 
effects of alterations in the external milieu on signal transduction systems, as the cell-to-
cell interactions remain and can be studied. As for any in vitro model, hippocampal slices 
have the disadvantage of being an isolated brain area removed from the circuitry of the 
intact brain. Also, some morphological changes are known to happen during slice 
incubation; increased swelling or condensation of some brain compartments and 
retraction of the finer astrocyttic processes (Fiala et al., 2003). However, hippocampal 
slices form a well defined and highly characterized test system, and has been invaluable for 
the studies presented in papers I and II of this thesis. 
 
Synaptic Vesicles 
Isolation of synaptic vesicles is a commonly used method to study the uptake ability of 
these organelles. When synaptic vesicles are isolated by simple differential centrifugations, 
the resulting vesicular fraction will, to a variable degree, be contaminated with other 
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cellular compartments. Contamination by myelin and cell membranes in crude synaptic 
vesicle fraction might be reduced by mixing the supernatant gained after the first low-
speed centrifugation step with sucrose, final concentration 0.8M (Mariussen and Fonnum, 
2001). Further purification of the synaptic vesicles may be performed with controlled-pore 
glass bead chromatography (Nagy et al., 1976;  Huttner et al., 1983;Jahn et al., 1985) or by 
immunoprecipitation with antibodies against obligatory synaptic proteins like 
synaptobrevin or synaptophysin (Burger et al., 1989; Burré et al., 2007). However, all these 
purification steps have the disadvantage that a considerable amount of synaptic vesicles is 
lost. For the experiments included in this thesis, synaptic vesicles from small brain regions 
were used and the amount of vesicles gained from each of these structures was limited, 
thus the crude synaptosomal fraction was used without further purifications. The observed 
uptake of aspartate and glutamate (paper II) can not be ascribed to plasma membrane 
EAATs in contaminating membrane-enclosed structures, as uptake via the EAATs require 
Na+ (Storck et al., 1992; Pines et al., 1992; Kanai and Hediger, 1992; Tanaka, 1993; Arriza 
et al., 1997), which was obmitted during the isolation- or incubation steps. 
 
Antibody Testing 
The use of antibodies for immunhistochemistry requires a great deal of caution, as cross-
reactivity and unspecific labelling might occur. This matter has been exhaustively discussed 
by Holmseth et al. (2005).  In a recent paper (Larsson et al., 2011) we highlighted the 
importance of testing antibodies in the same tissue as the analysis were performed, as 
cross-reactivity can be highly tissue-specific. The antibodies used in this thesis have been 
specificity-tested by Western blotting (for antibodies against proteins) and shown to give 
one principal band at the appropriate molecular weights. The antibodies against amino 
acids have been extensively characterized (Gundersen et al., 1993; 1998; 2001a; 2001b) 
yet, for each experiment, sandwiches of different amino acids conjugated to brain proteins 
(Ottersen et al., 1990) were included to verify that the antibodies labeled only the amino 
acid against which they were raised.  
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CONCLUDING REMARKS 
We have studied the mechanism underlying release of aspartate from nerve terminals and 
the effect of an antiepileptic drug, valproate, on cerebral levels of aspartate and 
glutamate. 
In particular, we have answered the following questions: 
How do synaptic terminals release aspartate? 
We have shown that aspartate is taken up into synaptic vesicles and presumably released 
by regulated exocytosis. Alternative release mechanisms, plasma membrane EAATs and 
VRACs have been excluded as important contributors to aspartate release under non-
pathological conditions (papers I and II).  
Is sialin the principal vesicular aspartate transporter?  
We used sialin knock-out mice and wild-types to show that sialin is not required for 
depletion of aspartate from nerve terminals in response to depolarization. Thus, vesicular 
accumulation of aspartate must be highly independent of sialin. 
Can the antiepileptic drug, valproate, reduce aspartergic neurotransmission? 
Acute treatment of rats with valproate, resulted in decreased levels of aspartate in 
excitatory and inhibitory nerve terminals, but not in stem dendrites, indicating an effect on 
the transmitter pool of aspartate. These results point to a possibly important clinical effect 
of valproate: reduced aspartergic neurotransmission. 
Is valproate neuroprotective against excitotoxicity? 
In response to two weeks of valproate treatment, the level of EAAT2 was increased, and 
the extracellular accumulation of aspartate and glutamate in response to a focal injection 
of a neurotoxin, malonate, was reduced. Consequently, valproate treated rats developed 
smaller lesions than the control animals did, indicating a neuroprotective effect of 
valproate treatment in vivo. 
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Vesicular Release of L- and D-Aspartate from Hippocampal Nerve Termi-
nals: Immunogold Evidence 
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Abstract: Glutamate is established as the most important excitatory transmitter in the brain. The transmitter status of as-
partate is debated. There is evidence that aspartate is released from nerve terminals by exocytosis. However, release 
through excitatory amino acid transporters (EAATs) could be an alternative mechanism. We further investigated this by 
use of light and quantitative electron microscopic immunocytochemistry. The nerve terminal localisation of aspartate was 
compared to that of glutamate using antibodies specifically recognising the amino acids. Rat hippocampal slices were in-
cubated under normal (3 mM) and depolarising (55 mM) concentrations of K+ with and without the excitatory amino acid 
transporter inhibitor threo-beta-benzyloxyaspartate (TBOA). If aspartate is released either through reversal of the EAATs 
or through exchange with synaptically released glutamate, we would expect that TBOA would block the depolarisation 
induced release of aspartate. We found, however, that there was a substantial depletion of aspartate, as well as of gluta-
mate, from hippocampal nerve terminals during K+ induced depolarisation in the presence of TBOA. The possibility that 
aspartate is released through exocytosis from synaptic vesicles was further investigated by the use of a D-aspartate uptake 
assay, including exposure of the slices to exogenous D-aspartate and the use of D-aspartate immunogold cytochemistry to 
localise D-aspartate in the fixed tissue. We found that D-aspartate taken up into the terminals was concentrated in synaptic 
vesicles as opposed to in the cytoplasmic matrix. This is in line with the presence in synaptic vesicles of the recently iden-
tified vesicular transporter for aspartate. 
Keywords: Synaptic vesicles, immunocytochemistry, amino acids, electron microscopy, transport. 
 The release of glutamate at synapses in the brain is well 
studied. Glutamate is released upon depolarisation of the 
presynaptic nerve terminal, leading to opening of voltage 
gated Ca2+ channels and Ca2+-dependent fusion of glutamate 
filled synaptic vesicles with the plasma membrane. The 
mechanism of release of L-aspartate at central synapses re-
mains less defined. L-aspartate has been shown to be re-
leased in a Ca2+ and clostridium toxin sensitive manner from 
various in vitro brain preparations (e.g. [1-7]). Strongly in 
favour of an exocytotic release mechanism are our previous 
immunocytochemical results showing that K+ induced depo-
larisation elicited depletion of L-aspartate from nerve end-
ings, which could be inhibited by low extracellular Ca2+-
concentrations and tetanus toxin [8-10]. In addition, D-
aspartate has been shown to be subject to exocytotic release 
both from cultured neurons [11] synaptosomes [12] and in-
tact brain tissue [13]. Taken together, these results indicate 
that synaptic vesicles harbour a transporter for L- and/or D-
aspartate (see [14]). This is in good agreement with a very 
recent study showing that hippocampal synaptic vesicles 
contain a vesicular excitatory amino acid transporter (VEAT) 
for aspartate and glutamate [15]. It was shown that sialin, a 
H+/sialic acid co-transporter belonging to the SLC17A5 
group of Na+/phosphate transporters, could carry also aspar-
tate and glutamate into synaptic vesicles [15]. 
*Address correspondence to this author at the Department of Anatomy and 
the CMBN, University of Oslo, POB 1105 Blindern, 0317 Oslo, Norway;  
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 There is ample evidence that excitatory nerve endings in 
the brain contain functional plasma membrane excitatory 
amino acid transporters (EAATs) [16-20]. The previous as-
partate release data do not clearly distinguish between L-
aspartate release via exocytosis and via these EAATs, which 
could release aspartate either through reversal of the trans-
porter or through heteroexchange with glutamate released 
from synaptic vesicles. Although some biochemical studies 
have given evidence that release through the EAATs does 
not play a pivotal role in the release of aspartate [12, 21], this 
has not been directly studied with high resolution at the mor-
phological level. In order to investigate the proportion of L-
aspartate release which is mediated through the EAATs, we 
incubated hippocampal slices with the non-transportable 
glutamate transporter inhibitor (2S,3S)-3-[3-(4-methoxyben-
zoylamino)benzyloxy]aspartate (PMB-TBOA)  during K+-
induced depolarisation. By using light- and electron micro-
scopic immunocytochemistry we compared the depletion of 
L-aspartate from excitatory nerve terminals with the deple-
tion of glutamate. To shed additional light on the vesicular 
release of aspartate we exposed the slices to exogenous D-
aspartate and used a quantitative D-aspartate immunogold 
method [16-18, 22] to analyse the synaptic vesicle content of 
D-aspartate that had been taken up into excitatory nerve ter-
minals.  
MATERIALS AND METHODOLOGY 
Hippocapal Slice Incubation 
 Hippocampal slice experiments were performed as previ-
ously described [8, 9, 18]. In brief, in each experiment we 
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harvested a brain from a decapitated Wistar rat (~200 g). 
Then the hippocampi were dissected out and cut in 0.3 mm 
thick slices. The slices were preincubated in oxygenated 
Krebs’ solution (126 mM NaCl, 3 mM KCl, 10 mM sodium 
phosphate buffer (pH 7.4), 1.2 mM CaCl2, 1.2 mM MgSO4 
and 10 mM glucose) for 1 h at 30 º C. The slices, which were 
subjected to EAAT inhibition, were transferred to a Krebs’ 
solution containing 30 M PMB-TBOA [18] during the last 
15 minutes of the preincubation. Then the slices were incu-
bated for 1 h at 30 °C in Krebs’ solution under physiological 
(3 mM) and depolarising (55 mM) concentrations of K
+
 with 
and without the EAAT-blocker PMB-TBOA (30 M) (6 
slice experiments). To characterise the localization of D-
aspartate taken up in the nerve terminals, after preincubation 
some slices were incubated for 15 minutes in Krebs’ solution 
at 3 mM K
+
 with and without 50 M D-aspartate (3 slice 
experiments). After incubation the slices were fixed in 2.5% 
glutaraldehyde and 1% formaldehyde for 1 h in room tem-
perature (about 20°C). The slices were stored in the fixative 
at 4°C until sectioning and embedding.  
Light Microscopic Immunocytochemistry 
 The hippocampal slices were cryo-protected in sucrose 
(30%) before 20 m thick sections were cut on a freezing 
microtome. Then the sections were subjected to immunocy-
tochemistry according to a three layer immunoperoxidase 
method. After incubation with primary antibodies (no 435 L-
aspartate (1:5000) and no 607 L-glutamate (1:5000)) over-
night at room temperature (about 20°C), the sections were 
treated with biotinylated donkey anti-rabbit Ig (Amersham, 
Little Chalfont Buckinghamshire, UK) and with streptavidin-
biotinylated horseraddish peroxidase (Amersham, Little 
Chalfont Buckinghamshire, UK), before the antigen-
antibody binding was visualized with hydrogen peroxide/di-
amino-benzidine.  
Electron Microscopic Immunocytochemistry
 The slices were embedded in Lowicryl HM20 as previ-
ously described [18, 22-24]. After the embedding ultrathin 
sections (80-100 nm) were cut perpendicular to the surface 
of the slices (so that immunogold analysis could be made at 
definite distances from the slice surface) and labelled with 
the 482 D-aspartate (1:300), 607 L-glutamate (1:5000) or 
435 L-aspartate (1:100) antisera. The primary antibodies 
were visualised with 15 nm gold particles coupled to secon-
dary anti-rabbit antibodies. The sections were studied in a 
Tecnai 12 or a Philips CM10 electron microscope. Electron 
micrographs were randomly taken from the CA1 stratum 
radiatum and the inner dentate molecular layer. The number 
of L-aspartate, D-aspartate and glutamate gold particles were 
counted in nerve terminals making asymmetric synapses on 
dendritic spines (excitatory synapses). The area of the nerve 
terminals (the area of mitochondria was not included) was 
estimated by point counting using an overlay screen [23] and 
the gold particle densities were calculated. The results were 
statistically evaluated by a non-parametric Mann-Whitney U 
test (Statistica).  
 For the analysis of D-aspartate in synaptic vesicles gold 
particles signalling D-aspartate and grid points for area de-
termination were recorded over synaptic vesicles and cyto-
plasmic matrix (areas free of vesicles and mitochondria) in 
excitatory nerve terminals. Synaptic vesicles were identified 
as round, clear membrane bounded structures with a diame-
ter ranging from 20 to 80 nm [9]. As the lateral resolution of 
the immunogold method is about 30-40 nm [25, 26], which 
is similar to the diameter of the synaptic vesicles and to the 
section thickness, the method cannot localize a gold particle 
to a single vesicle. To by pass this problem, gold particles 
were ascribed to synaptic vesicles if the particle centres were 
within a 30 nm distance from the outer border of the vesi-
cles. To correct for the contamination of the vesicle labelling 
with the cytoplasmic matrix labelling, the gold particle den-
sities recorded over cytoplasmic matrix were subtracted from 
the gold particle densities recorded for the vesicles. The ar-
eas of the profiles included in the analysis were determined 
by point counting using an overlay screen [23]. The densities 
of D-aspartate immunogold particles (average number of 
gold particles/Hm2) in the different tissue profiles were cal-
culated and the results statistically evaluated by a non-
parametric test (Mann-Whitney-U, Statistica).
Specificity of the Antibodies 
 The rabbit no 607 L-glutamate, no 435 L-aspartate and 
no 482 D-aspartate antisera have been previously character-
ized [9, 10, 16, 27]. To avoid possible cross-reactivities the 
L-glutamate, L-aspartate and D-aspartate antisera were used 
with the addition of 0.2 mM complexes of glutaralde-
hyde/formaldehyde treated L-aspartate plus glutamine and L-
asparagine, L-glutamate plus GABA and L-glutamate plus 
L-aspartate, respectively. As a specificity control for each 
immunoperoxidase incubation, spots of conjugates of differ-
ent amino acids linked to brain macromolecules by glutaral-
dehyde/formaldehyde were placed on cellulose nitrate-
acetate filters and incubated along with the tissue sections [8, 
9]. For the immunogold experiments conjugates were made 
according to [28]. The concentration of the fixed amino acids 
in the embedded conjugate clumps is about 100 mM [28]. 
These test systems showed that the primary antibodies only 
labelled the conjugate containing the amino acid against 
which the antibodies were raised. Furthermore, the gluta-
mate, L-aspartate and D-aspartate immunoreactivities of 
tissue and test sections were blocked by adding 0.3 mM of 
aldehyde treated glutamate, L-aspartate or D-aspartate, re-
spectively, to the antisera. The relationship between the den-
sity of L-aspartate, D-aspartate and glutamate immunogold 
particles and the concentration of fixed glutamate in the tis-
sue was linear, as assessed by simultaneously processed test 
sections with conjugates containing known concentrations of 
glutamate, L-aspartate and D-aspartate [16, 29]. 
RESULTS 
Effects of Membrane Depolarisation and TBOA  
 We have previously shown that K
+
 induced membrane 
depolarisation causes aspartate, in the same manner as glu-
tamate, to be depleted from excitatory nerve endings in a 
Ca
2+
-dependent and tetanus toxin sensitive manner [8,9]. The 
question is whether such a depletion of aspartate could be 
caused by heteroexchange through the EAATs with exocyto-
sed glutamate. An ideal tool for investigating this would be 
to use a non-transportable blocker of the EAATs during 
membrane stimulation, such as threo-beta-benzyloxy-
aspartate (TBOA) [30]. In a recent study we showed that  
30 M PMB-TBOA, which is a potent blocker of EAAT1-3 
[31], totally inhibits D-aspartate transport in exci-tatory 
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nerve endings (but not in astrocytes, see below) in hippo-
campal slices [18].  
 As observed previously [8, 9] we here show that in slices 
incubated with 3 mM K+ the aspartate and glutamate anti-
bodies produced a zonal labelling pattern corresponding to 
the nerve terminal field of the excitatory afferents in hippo-
campus (Fig. 1A, 1B). The aspartate and glutamate staining 
were mostly located in small dots (insets in Fig. 1A and B)
along weakly labelled dendritic structures. Electron micro-
scopic immunogold cytochemistry [9] confirmed that the 
Fig. (1). The K+-induced depletion of aspartate and glutamate from nerve ending-like dots was not substantially inhibited by PMB-TBOA. At 
physiological K+-concentrations (3 mM) aspartate (A) and glutamate (B) immunoreactivities were located in dots (insets in A and B) corre-
sponding to the excitatory nerve terminals in the hippocampus. At 55 mM K+ the aspartate (C) and glutamate (D) staining mostly disap-
peared from the nerve terminal-like dots and accumulated in astroglial cells (insets in C and D), including in those around blood vessels 
(perivascular astroglia). At 55 mM K+ in the presence of PMB-TBOA the aspartate (E) and glutamate (F) staining pattern was approximately 
unchanged, still showing that the most prominent staining was located in astroglial cells (insets in E and F). Similar aspartate and glutamate 
labelling patterns were observed in 6 slice experiments. Symbols: P, str. pyramidale; R, str. radiatum; M, dentate molecular layers. Bars: 200 
m, 20 m (insets). 
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dotted staining represents labelling of nerve terminals mak-
ing asymmetric synapses with dendritic spines (i.e. synapses 
with an “excitatory appearance”) (Fig. 2A, 2B). Thus, we 
call the labelled dots nerve ending-like dots. When the slices 
were depolarised with a high K+ concentration (50 mM) the 
aspartate and glutamate immunoreactivities were depleted 
from the nerve ending like dots. Instead, the staining ap-
peared in astrocytes (Fig. 1C, 1D). Immunelectron micros-
copy of slices exposed to membrane depolarisation showed a 
robust reduction in the content of gold particles signalling 
aspartate and glutamate in excitatory nerve terminals (Fig. 
2C, 2D). This was substantiated by quantitative immunogold 
analysis, which showed that K+-induced depolarisation 
caused the nerve terminal densities of aspartate and gluta-
mate immunogold particles to be significantly reduced (Fig. 
3). Taken together, this suggests that aspartate and glutamate 
is released from nerve terminals and taken up into astrocytes 
when the neurons are depolarised.  
 At 3 mM K+ PMB-TBOA did not have any effect on the 
aspartate and glutamate labelling patterns (not shown). Dur-
ing depolarisation with 55 mM K+, the slices which were 
treated with PMB-TBOA showed a redistribution from a 
nerve ending like staining pattern to an astrocyte like stain-
ing pattern (Fig. 1E, 1F), similar to that observed at 55 mM 
K+ without PMB-TBOA (Fig. 1C and 1D). The uptake of 
aspartate and glutamate in astrocytes during K+ stimulation 
in the presence of TBOA probably occurs through a sodium 
dicarboxylate transporter [18]. The immunogold labellings 
revealed that the densities of gold particles signalling aspar-
tate and glutamate were somewhat higher in the depolarised 
terminals exposed to PMB-TBOA than in the terminals not 
exposed to PMB-TBOA, but lower than in the terminals 
from slices incubated at 3 mM K+ (Figs. 2E, 2F and 3). The 
immunogold quantifications (Fig. 3) showed that about 30% 
and 36% of the L-aspartate and glutamate immunogold par-
ticles depleted from the terminals during depolarisation 
could be blocked by PMB-TBOA. This indicates that about 
64-70 % of immunogold particles signalling L-aspartate and 
glutamate are depleted from the terminals due to exocytosis. 
Localisation of D-Aspartate Immunogold Particles 
 As we found that the contribution from the EAATs for 
the total release of aspartate from nerve terminals was rela-
tively minor, and several lines of evidence suggest that both 
L- and D-aspartate could be released by exocytosis (see In-
troduction), there should be a transporter capable of pumping 
L- and D-aspartate into synaptic vesicles (see Miyaji et al.
2008). To further investigate this uptake process we made 
use of a D-aspartate uptake assay, in which hippocampal 
slices were incubated with exogenous D-aspartate (50 M), 
fixed with glutar- and formaldehyde and subjected to elec-
tron microscopic immunogold cytochemistry using specific 
antibodies against D-aspartate [16-18, 22]. As D-aspartate is 
very slowly metabolised [32], it is “trapped” in the cellular 
compartment into which it was taken up. 
 Slices not exposed to D-aspartate did not contain any 
significant D-aspartate immunogold signal (not shown, see 
[16-18, 22]). In contrast, slices exposed to 50 M D-
aspartate showed clear sign of D-aspartate uptake in excita-
tory nerve terminals (Fig. 4A and C) (as well as in astrocytic 
processes (not shown, see [16]). A closer examination of the 
labelled terminals showed that D-aspartate gold particles 
were located over synaptic vesicles (insets in Fig. 4A and 
Fig. 4B). Interestingly, when quantifying the density of D-
Fig. (2). Electron micrographs showing gold particles signalling aspartate (A, C, E) and glutamate (B, D, F) in excitatory synapses between 
nerve terminals (ter) and postsynaptic spines (sp) in hippocampal slices incubated at 3 mM K+ (A and B), 55 mM K+ (C and D) and 55 mM 
K+ plus PMB-TBOA (E and F). Note that both aspartate and glutamate are depleted from the terminals upon stimulation with an elevated 
concentration of K+ and that the treatment with PMB-TBOA does not block this depletion. Symbol: mito, mitochondria. Scale bar: 200 nm. 
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aspartate immunogold particles over synaptic vesicles and 
cytoplasmic matrix in the excitatory terminals (see Meth-
ods), we found that the gold particle density was much 
higher over the former than the latter compartment, giving a 
synaptic vesicle/cytoplasmic matrix ratio of about 9. From 
test sections with known concentrations of D-aspartate incu-
bated with the D-aspartate antibodies in parallel with the 
hippocampal sections [22] we could estimate that the fixed 
D-aspartate concentration in the cytoplasmic matrix was 
about 2 mM, whereas the D-aspartate concentration in syn-
aptic vesicles was about 18 mM.  
DISCUSSION 
 Previously we have shown that the depletion of aspartate 
and glutamate from excitatory nerve terminals is sensitive to 
low Ca2+ conditions and tetanus toxin [9]. This result could 
be explained by the possibility that it is glutamate that is 
released from synaptic vesicles, whereas aspartate is released 
from the cytosol through EAAT mediated heteroexchange 
with synaptically released glutamate. In this way the aspar-
tate release would seemingly appear as exocytotic. However, 
here we show that there is a substantial depletion of both 
aspartate and glutamate form excitatory nerve terminals dur-
ing K+ induced depolarisation, despite the presence of the 
EAAT blocker TBOA. This strongly suggests that release 
through the EAATs cannot account for the overall release of 
aspartate from the terminals, indicating that at a major part 
of the released aspartate during K+ stimulation is derived 
from exocytosis of synaptic vesicles.  
 Our previous immunogold results from excitatory nerve 
terminals show that there is a residual depolarisation induced 
depletion of aspartate and glutamate, which is not blocked by 
conditions inhibiting exocytosis [9]. Thus, parts of the aspar-
tate and glutamate release could be mediated by the EAATs. 
The non-exocytotic aspartate and glutamate depletion is 
about 30-40% of the total depletion during K+ triggered de-
polarisation [9]. This fits with the present data showing that 
approximately 30-36% of aspartate and glutamate released 
from the excitatory terminals could be blocked by blocking 
the EAATs. These data suggest that a minor fraction of as-
partate and glutamate released from the terminals escapes 
through the EAATs, whereas the largest fraction (about 
70%) is released through exocytosis. 
 The present data, showing that the depletion of aspartate 
and glutamate from the nerve terminals is inhibited to a simi-
lar extent by blocking the EAATs, is compatible with the 
notion that the non-exocytotic release of the excitatory 
amino acids during K+-induced depolarisation is caused by a 
reversal of the nerve terminal EAATs. This is in line with 
biochemical data, showing that the K+-induced release of 
newly taken up D-aspartate from hippocampal nerve endings 
occurs in part by exocytosis (about 65%) and in part by 
transporter reversal (about 35%) [12]. 
 Our finding that the ratio of D-aspartate labelling be-
tween synaptic vesicles and cytoplasmic matrix was about 9 
supports the idea that aspartate can be taken up into synaptic 
vesicles before exocytotic release. This uptake is mediated 
by other transporters than the vesicular glutamate transport-
Fig. (3). Quantitative representation of the density of aspartate (A) and glutamate (B) immunogold particles in excitatory nerve terminals in 
hippocampal slices incubated with 3 mM K+ (n=45 nerve terminals in A and B), 55 mM K+ (n=40 terminals in A and B) and 55 mM K+ in 
the presence of PMB-TBOA (n=42 nerve terminals in A and B). Asterisks denote that aspartate and glutamate values at 3 K+ are significantly 
different from those at 55K+ and 55K+ + TBOA and that the values at 55K+ are significantly different from those at 55K+ + TBOA (p<0.01, 
Mann-Whitney-U test, two tails). The results are from one slice experiment. The same results were obtained in another experiment. 
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ers (VGLUTs), which neither transport L-aspartate nor D-
aspartate [33-39]. Even though Miyaji et al. [15] did not give 
any information about vesicular D-aspartate uptake, the pre-
sent data are in good agreement with their identification of a 
vesicular excitatory amino acid transporter that carries both 
aspartate and the aspartate analogue threo-hydroxy aspartate 
[5] into hippocampal synaptic vesicles [15]. Our results also 
support those of Fleck and co-workers [14], who showed that 
radiolabelled L- and D-aspartate could be taken up in synap-
tic vesicles, which were immunoisolated with synaptophysin 
after amino acid preincubation of intact synaptosomes. How-
ever, it should be noted that especially the L-aspartate uptake 
data from this study should be interpreted with caution. Dur-
ing the preincubation of the synaptosomes some of the radio-
label on L-aspartate could have been transferred to L-
glutamate through metabolism in the Krebs’ cycle. However, 
as D-aspartate is very slowly metabolised in the brain [32], 
the possibility that such a mechanism underlies the result of 
the D-aspartate uptake experiments of [14] is not very likely. 
Thus, the present results and those of Fleck and co-workers 
[14] strongly suggest that also D-aspartate is transported into 
synaptic vesicles, probably by the same transporter as L-
aspartate. This is in line with the large body of evidence 
showing exocytosis of both L-aspartate [1-4, 6-10, 14] and 
D-aspartate [11, 12, 40-45].  
 We found that the cytoplasmic concentration of D-
aspartate (about 2 mM) after uptake into nerve terminals was 
in the range of the apparent Km values for aspartate uptake 
into synaptic vesicles reported both by Miyaji et al. [15] and 
Fleck et al. [14]. The substrate specificity of VEAT indicates 
that it carries both glutamate and aspartate. This may explain 
the previous immunogold findings of glutamate and aspar-
tate in the same nerve terminals [9, 27]. There are so far no 
detailed electron microscopic localisation studies of VEAT 
in the brain, only previous light microscopic results showing 
that the sialin protein (see Introduction) is present at quite 
high concentrations throughout the forebrain, including in 
the hippocampus [46, 47]. Whether vesicles containing 
VEAT is located in the same terminals as those containing 
VGLUT is one important question that must await further 
studies.  
 The conclusion from previous uptake studies using whole 
brain isolated synaptic vesicles is that the vesicles do not 
transport aspartate [48-52]. However, most of these studies 
did not analyse direct uptake of radiolabelled aspartate, but 
showed that neither L- nor D-aspartate could inhibit uptake 
of L-glutamate into synaptic vesicles. This indicates that L- 
and D-aspartate are not transported by the same transporter 
proteins as glutamate, but does not exclude the possibility 
that aspartate is transported by another vesicular transporter, 
such as VEAT [15]. It should, however, be noted that the 
initial study of Naito and Ueda [48] showed that whole brain 
synaptic vesicles could indeed accumulate L-aspartate, al-
though the uptake was much lower (7.5%) than that of L-
glutamate. In the studies of Miyaji et al. [15] threo-hydroxy 
aspartate could not significantly inhibit glutamate uptake 
into whole brain synaptic vesicles (only into hippocampal 
vesicles), indicating that VEAT is much less abundant that 
the VGLUTs. 
CONCLUSION 
 We here show that excitatory synaptic vesicles in the 
hippocampus can accumulate D-aspartate and release L-
aspartate by exocytosis, further corroborating the evidence 
for a vesicular aspartate transporter [15] in these vesicles. 
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ŝŶƌĞƐƉŽŶƐĞƚŽǀĂůƉƌŽĂƚĞƚƌĞĂƚŵĞŶƚ͕ĂŶĚƉŽŝŶƚƐƚŽĂŶĞǁŵĞĐŚĂŶŝƐŵŽĨĂĐƟŽŶĨŽƌǀĂůƉƌŽĂƚĞ͘
ĞĐŝůŝĞDŽƌůĂŶĚĂ͕<ĂũĂEŽƌĚĞŶŐĞŶĂĂŶĚsŝĚĂƌ'ƵŶĚĞƌƐĞŶĂ͕ď
ĂͿĞƉĂƌƚŵĞŶƚŽĨŶĂƚŽŵǇĂŶĚƚŚĞDE͕hŶŝǀĞƌƐŝƚǇŽĨKƐůŽ͕EŽƌǁĂǇ͘ďͿĞƉĂƌƚŵĞŶƚŽĨEĞƵƌŽůŽŐǇ͕ KƐůŽhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂů͕KƐůŽ͕EŽƌǁĂǇ͘
<ĞǇǁŽƌĚƐ͗
ĂƐƉĂƌƚĂƚĞ
ǀĂůƉƌŽĂƚĞ
ĞƉŝůĞƉƐǇ
ŶĞƵƌŽƚƌĂŶƐŵŝƐƐŝŽŶ
ŶĞƌǀĞƚĞƌŵŝŶĂů
ĞǆĐŝƚŽƚŽǆŝĐŝƚǇ
ĐŽƌƌĞƐƉŽŶĚĞŶĐĞƐŚŽƵůĚďĞĂĚĚƌĞƐƐĞĚ
ƚŽ͗ĞĐŝůŝĞDŽƌůĂŶĚ͕ĞƉĂƌƚŵĞŶƚŽĨ
ŶĂƚŽŵǇĂŶĚƚŚĞDE͕hŶŝǀĞƌƐŝƚǇŽĨ
KƐůŽ͕WKϭϭϬϱůŝŶĚĞƌŶ͕ϬϯϭϳKƐůŽ͕
EŽƌǁĂǇ͘WŚŽŶĞ͗нϰϳϮϮϴϱϭϮϱϵ
&Ăǆ͗нϰϳϮϮϴϱϭϮϳϴ
ŵĂŝů͗ĐĞĐŝůŝĞ͘ŵŽƌůĂŶĚΛŵĞĚŝƐŝŶ͘ƵŝŽ͘ŶŽ͘
Zd/>/E&K ^dZd
/ŶƚƌŽĚƵĐƟŽŶ
sĂůƉƌŽĂƚĞ ŝƐŽŶĞŽĨ ƚŚĞŵŽƐƚǁŝĚĞůǇƵƐĞĚĚƌƵŐƐ ŝŶŶĞƵƌŽůŽŐǇ
ĂŶĚƉƐǇĐŚŝĂƚƌǇ͕ ĂŶĚŚĂƐďĞĞŶƵƐĞĚŝŶƚŚĞƚƌĞĂƚŵĞŶƚŽĨĞƉŝůĞƉƐǇ
ĨŽƌŵŽƌĞ ƚŚĂŶ ϯϬ ǇĞĂƌƐ͘ zĞƚ ŝƚƐŵĂŝŶŵĞĐŚĂŶŝƐŵŽĨ ĂĐƟŽŶ ŝƐ
ƐƟůůƵŶĐůĞĂƌ͘ sĂůƉƌŽĂƚĞŚĂƐĂďƌŽĂĚƐƉĞĐƚƌƵŵŽĨĞīĞĐƚƐĂŐĂŝŶƐƚ
ďŽƚŚŐĞŶĞƌĂůŝƐĞĚĂŶĚƉĂƌƟĂůƐĞŝǌƵƌĞƐ͕ĂƐǁĞůůĂƐĂŐĂŝŶƐƚďŝƉŽůĂƌ
ĚŝƐŽƌĚĞƌƐ ΀ϯϴ΁͘ ^ĞǀĞƌĂů ŵĞĐŚĂŶŝƐŵƐ ŚĂǀĞ ďĞĞŶ ƉƌŽƉŽƐĞĚ ƚŽ
ĞǆƉůĂŝŶ ƚŚĞĐůŝŶŝĐĂůĂĐƟŽŶŽĨǀĂůƉƌŽĂƚĞ͕ ŝŶĐůƵĚŝŶŐ ŝŶŚŝďŝƟŽŶŽĨ
ǀŽůƚĂŐĞͲŐĂƚĞĚƐŽĚŝƵŵĐŚĂŶŶĞůƐ΀ϯϭ͖ϰϬ΁͕ŝŶŚŝďŝƟŽŶŽĨŶĞƵƌŽŶĂů
ĞŶĞƌŐǇŵĞƚĂďŽůŝƐŵ΀Ϯϭ΁ĂŶĚĞīĞĐƚƐŽŶŶĞƵƌŽƚƌĂŶƐŵŝƩĞƌĂŵŝŶŽ
ĂĐŝĚƐ ΀ϯϮ͖ϯϯ΁͘ ƚ ƚŚĞƌĂƉĞƵƟĐĂůůǇ ƌĞůĞǀĂŶƚ ĐŽŶĐĞŶƚƌĂƟŽŶƐ͕ ŝƚ ŝƐ
ƵŶĐůĞĂƌ ŝĨ ĚŝƌĞĐƚ ŝŶŚŝďŝƟŽŶ ŽĨ ǀŽůƚĂŐĞͲŐĂƚĞĚ ƐŽĚŝƵŵ ĐŚĂŶŶĞůƐ
ĐŽŶƚƌŝďƵƚĞƐ ƚŽ ƚŚĞ ĐůŝŶŝĐĂů ĞīĞĐƚŽĨ ǀĂůƉƌŽĂƚĞ ;ĨŽƌ ƌĞǀŝĞǁ͕ ƐĞĞ
΀ϮϬ͖Ϯϳ΁Ϳ͘/ŶƐƚĞĂĚ͕ŝŶĐƌĞĂƐĞĚ'ĞƌŐŝĐƚƌĂŶƐŵŝƐƐŝŽŶŝƐďĞůŝĞǀĞĚ
ƚŽďĞŚŝŐŚůǇŝŵƉŽƌƚĂŶƚďŽƚŚĨŽƌƚŚĞĂĐƵƚĞĂŶĚůŽŶŐͲƚĞƌŵĞīĞĐƚƐ
ŽĨ ǀĂůƉƌŽĂƚĞ͘ /ƚ ŝƐ ǁĞůů ŬŶŽǁŶ ƚŚĂƚ ' ĂĐĐƵŵƵůĂƚĞƐ ŝŶ ƚŚĞ
ďƌĂŝŶĂŌĞƌǀĂůƉƌŽĂƚĞƚƌĞĂƚŵĞŶƚ΀ϭ͖ϭϭ͖Ϯϲ͖Ϯϵ͖ϯϬ΁͘dŚĞŝŶĐƌĞĂƐĞŝŶ
'ŝƐƚŚŽƵŐŚƚƚŽŽĐĐƵƌƐĞůĞĐƟǀĞůǇŝŶ'ĞƌŐŝĐƚĞƌŵŝŶĂůƐ΀Ϯϲ΁͘
sĂůƉƌŽĂƚĞĂůƐŽĐĂƵƐĞƐ ƚŚĞďƌĂŝŶ ůĞǀĞůƐŽĨ ƚŚĞĞǆĐŝƚĂƚŽƌǇ ƚƌĂŶƐͲ
ŵŝƩĞƌ ĂƐƉĂƌƚĂƚĞ ƚŽ ĚĞĐƌĞĂƐĞ ΀ϮϮ͖ϯϵ΁͘ dŚĞ ĞīĞĐƚ ŽĨ ǀĂůƉƌŽĂƚĞ
ŽŶƚŚĞĚŝƐƚƌŝďƵƟŽŶŽĨĂƐƉĂƌƚĂƚĞďĞƚǁĞĞŶĚŝīĞƌĞŶƚƐƵďĐĞůůƵůĂƌ
ŶĞƵƌŽŶĂů ĐŽŵƉĂƌƚŵĞŶƚƐ͕ ŚŽǁĞǀĞƌ͕  ƌĞŵĂŝŶƐ ƵŶŬŶŽǁŶ͘ /Ĩ
ǀĂůƉƌŽĂƚĞ ƉƌĞĚŽŵŝŶĂŶƚůǇ ƌĞĚƵĐĞƐ ĂƐƉĂƌƚĂƚĞ ůĞǀĞůƐ ŝŶ ŶĞƌǀĞ
ƚĞƌŵŝŶĂůƐ͕ ƚŚĞ ƚƌĂŶƐŵŝƩĞƌ ƌĞůĞĂƐŝŶŐĐŽŵƉĂƌƚŵĞŶƚ͕ ƚŚŝƐǁŽƵůĚ
ƐƵŐŐĞƐƚ ƚŚĂƚ ǀĂůƉƌŽĂƚĞ ůĞĂĚƐ ƚŽ ƌĞĚƵĐĞĚ ĞǆĐŝƚĂƚŽƌǇ ƐǇŶĂƉƟĐ
ĂĐƟǀŝƚǇ͕  ŝŶ ƚƵƌŶ ƉŽŝŶƟŶŐ ƚŽ ĂŶ ĂĚĚŝƟŽŶĂůŵĞĐŚĂŶŝƐŵ ĨŽƌ ƚŚĞ
ĐůŝŶŝĐĂůĂĐƟŽŶŽĨǀĂůƉƌŽĂƚĞ͘
DĂƚĞƌŝĂůƐĂŶĚDĞƚŚŽĚƐ
ŶŝŵĂů ŚĂŶĚůŝŶŐ ǁĂƐ ŝŶ ƐƚƌŝĐƚ ĂĐĐŽƌĚĂŶĐĞ ǁŝƚŚ ůŽĐĂů ĂŶĚ
ŶĂƟŽŶĂůĞƚŚŝĐĂůŐƵŝĚĞůŝŶĞƐ͘DĂůĞtŝƐƚĂƌƌĂƚƐ;ŶсϯŝŶĞĂĐŚŐƌŽƵƉͿ
ǁĞƌĞŐŝǀĞŶĂŶŝŶƚƌĂƉĞƌŝƚŽŶĞĂů;ŝ͘Ɖ͘ͿŝŶũĞĐƟŽŶŽĨƐŽĚŝƵŵǀĂůƉƌŽĂƚĞ
;ϰϬϬŵŐͬŬŐͿŽƌƐĂůŝŶĞ;Ϭ͘ϵйͿ͘ƚϯϬŵŝŶƵƚĞƐĂŌĞƌƚŚĞŝŶũĞĐƟŽŶ͕
ƚŚĞƌĂƚƐǁĞƌĞĂŶĂĞƐƚŚĞƟƐĞĚǁŝƚŚƉĞŶƚŽďĂƌďŝƚĂů;ϭϬϬŵŐͬŬŐ͕ŝ͘Ɖ͘Ϳ
ĂŶĚ ƚƌĂŶƐĐĂƌĚŝĂůůǇ ƉĞƌĨƵƐĞĚ ǁŝƚŚ Ă ŵŝǆƚƵƌĞ ŽĨ Ϯ͘ϱй ŐůƵƚĂƌͲ
ĂůĚĞŚǇĚĞ ĂŶĚ ϭй ƉĂƌĂĨŽƌŵĂůĚĞŚǇĚĞ ŝŶ ƉŚŽƐƉŚĂƚĞ ďƵīĞƌ ;Ɖ,
ϳ͘ϰͿ͘ dŚĞ ďƌĂŝŶƐ ǁĞƌĞ ŐĞŶƚůǇ ƌĞŵŽǀĞĚ͕ ĂŶĚ ƚŚĞ ŚŝƉƉŽĐĂŵƉĂů
ϯ ƌĞŐŝŽŶ ǁĂƐ ĚŝƐƐĞĐƚĞĚ ŽƵƚ ĂŶĚ ĞŵďĞĚĚĞĚ ŝŶ >ŽǁŝĐƌǇů
,DϮϬĂƐƉƌĞǀŝŽƵƐůǇĚĞƐĐƌŝďĞĚ΀Ϯ΁͘ŌĞƌĞŵďĞĚĚŝŶŐ͕ƵůƚƌĂƚŚŝŶ
ƐĞĐƟŽŶƐ ;ϴϬͲϭϬϬ ŶŵͿ ǁĞƌĞ ĐƵƚ ĂŶĚ ůĂďĞůůĞĚ ǁŝƚŚ ƚŚĞ ϰϯϱ >Ͳ
ĂƐƉĂƌƚĂƚĞ ;ϭ͗ϯϬϬͿ͕ ϲϬϳ >ͲŐůƵƚĂŵĂƚĞ ;ϭ͗ϯϬϬϬͿ Žƌ ϵϵϬ '
;ϭ͗ϯϬϬͿ ĂŶƟƐĞƌĂ͘ dŚĞƐĞ ĂŶƟƐĞƌĂ ŚĂǀĞ ďĞĞŶ ǁĞůů ĐŚĂƌĂĐƚĞƌͲ
ŝƐĞĚ ΀ϰ͖ϭϮͲϭϰ͖ϭϴ͖ϭϵ΁͘ dŽ ĂǀŽŝĚ ƉŽƐƐŝďůĞ ĐƌŽƐƐͲƌĞĂĐƟǀŝƟĞƐ͕ ƚŚĞ
ŐůƵƚĂŵĂƚĞ͕ ĂƐƉĂƌƚĂƚĞ ĂŶĚ ' ĂŶƟƐĞƌĂǁĞƌĞ ƵƐĞĚǁŝƚŚ ƚŚĞ
ĂĚĚŝƟŽŶ ŽĨ ƐŽůƵďůĞ ĐŽŵƉůĞǆĞƐ ;Ϭ͘Ϯ ŵDͿ ŽĨ ŐůƵƚĂƌĂůĚĞŚǇĚĞͬ
ĨŽƌŵĂůĚĞŚǇĚĞͲƚƌĞĂƚĞĚ >ͲĂƐƉ ĂƚĞ ƉůƵƐ ŐůƵƚĂŵŝŶĞ͕ ĂŶĚ >Ͳ
ĂƐƉĂƌĂŐŝŶĞ͕>ͲŐůƵƚĂŵĂƚĞƉůƵƐ'͕ĂŶĚ>ͲŐůƵƚĂŵĂƚĞ͕>ͲĂƐƉĂƌƚĂƚĞ
ƉůƵƐ ɴͲĂůĂŶŝŶĞ͕ ƌĞƐƉĞĐƟǀĞůǇ͘ Ɛ Ă ƐƉĞĐŝĮĐŝƚǇ ƚĞƐƚ͕ ƵůƚƌĂƚŚŝŶ
ƚĞƐƚƐĞĐƟŽŶƐĐŽŶƚĂŝŶŝŶŐǀĂƌŝŽƵƐĂŵŝŶŽĂĐŝĚƐĐŽŶũƵŐĂƚĞĚƚŽďƌĂŝŶ
ƉƌŽƚĞŝŶďǇĨŽƌŵͲĂŶĚŐůƵƚĂƌĂůĚĞŚǇĚĞ΀ϯϲ΁ǁĞƌĞ ůĂďĞůůĞĚĂůŽŶŐ
ǁŝƚŚ ƚŚĞƟƐƐƵĞƐĞĐƟŽŶƐ͘dŚĞƐĞ ƚĞƐƚ ƐǇƐƚĞŵƐƐŚŽǁĞĚ ƚŚĂƚ ƚŚĞ
ƉƌŝŵĂƌǇ ĂŶƟďŽĚŝĞƐ ŽŶůǇ ůĂďĞůůĞĚ ƚŚĞ ĐŽŶũƵŐĂƚĞ ĐŽŶƚĂŝŶŝŶŐ
ƚŚĞĂŵŝŶŽĂĐŝĚĂŐĂŝŶƐƚǁŚŝĐŚƚŚĞĂŶƟďŽĚŝĞƐǁĞƌĞƌĂŝƐĞĚ;ŶŽƚ
ƐŚŽǁŶͿ͘dŚĞƉƌŝŵĂƌǇĂŶƟďŽĚŝĞƐǁĞƌĞǀŝƐƵĂůŝƐĞĚǁŝƚŚĐŽůůŽŝĚĂů
ŐŽůĚĐŽŶũƵŐĂƚĞĚŐŽĂƚĂŶƟͲƌĂďďŝƚ/Ő';ƌŝƟƐŚŝŽĐĞůů/ŶƚĞƌŶĂƟŽŶĂů͖
ĂƌĚŝī͕h<Ϳ͘dŚĞƐĞĐƟŽŶƐǁĞƌĞƐƚƵĚŝĞĚŝŶĂdĞĐŶĂŝϭϮĞůĞĐƚƌŽŶ
ŵŝĐƌŽƐĐŽƉĞ͘ dŽ ǀŝƐƵĂůŝƐĞ ĂƐƉĂƌƚĂƚĞ ĂŶĚ ŐůƵƚĂŵĂƚĞͬ' ŝŶ
ƚŚĞ ƐĂŵĞ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ͕ ǁĞ ƉĞƌĨŽƌŵĞĚ ĚŽƵďůĞ ůĂďĞůůŝŶŐ
ĞǆƉĞƌŝŵĞŶƚƐ͕ŝŶǁŚŝĐŚƚŚĞƵůƚƌĂƚŚŝŶƐĞĐƟŽŶƐǁĞƌĞĮƌƐƚƚƌĞĂƚĞĚ
ǁŝƚŚƚŚĞĂƐƉĂƌƚĂƚĞĂŶƟďŽĚŝĞƐĂŶĚƚŚĞŶǁŝƚŚƚŚĞŐůƵƚĂŵĂƚĞŽƌ
'ĂŶƟďŽĚŝĞƐ͘ĞƚǁĞĞŶƚŚĞĮƌƐƚĂŶĚ ƚŚĞƐĞĐŽŶĚƐƚĞƉ͕ ƚŚĞ
ƐĞĐƟŽŶƐǁĞƌĞƐƵďũĞĐƚĞĚƚŽĨŽƌŵĂůĚĞŚǇĚĞǀĂƉŽƵƌ;ϴϬΣ͕ϭŚŽƵƌͿ
ƚŽ ƉƌĞǀĞŶƚ ŝŶƚĞƌĨĞƌĞŶĐĞ ďĞƚǁĞĞŶ ƚŚĞ ƐĞƋƵĞŶƟĂů ŝŶĐƵďĂƟŽŶƐ
΀ϯϳ΁͘ ^ĞĐŽŶĚĂƌǇ ĂŶƟďŽĚŝĞƐ ĐŽƵƉůĞĚ ƚŽ ϭϬ ĂŶĚ ϭϱ Ŷŵ ŐŽůĚ
ƉĂƌƟĐůĞƐǁĞƌĞƵƐĞĚ ŝŶ ƚŚĞĮƌƐƚĂŶĚƐĞĐŽŶĚƐƚĞƉ͕ ƌĞƐƉĞĐƟǀĞůǇ͘
ůĞĐƚƌŽŶ ŵŝĐƌŽŐƌĂƉŚƐ ǁĞƌĞ ƌĂŶĚŽŵůǇ ƚĂŬĞŶ ĨƌŽŵ ƚŚĞ ϯ
ƐƚƌĂƚƵŵ ƌĂĚŝĂƚƵŵ͕ ŐƌĂŶƵĂůͲ Žƌ ƉǇƌĂŵŝĚĂů ĐĞůů ůĂǇĞƌ͘  dŚĞ
ƚĞƌŵŝŶĂůƐ ƚŽ ďĞ ŝŶĐůƵĚĞĚ ŝŶ ƚŚĞ ƐƚƵĚǇ ǁĞƌĞ ĐŚŽƐĞŶ Ăƚ ůŽǁ
ŵĂŐŶŝĮĐĂƟŽŶ͕ǁŚĞƌĞƚŚĞϭϬŶŵĂƐƉĂƌƚĂƚĞŐŽůĚƉĂƌƟĐůĞƐǁĞƌĞ

6XEPLWWHG
ǁĞƌĞŶŽƚǀŝƐŝďůĞ͕ĂŶĚĂůůƋƵĂŶƟƚĂƟǀĞĂŶĂůǇƐŝƐǁĞƌĞƉĞƌĨŽƌŵĞĚ
ďǇ Ă ďůŝŶĚĞĚ ŽďƐĞƌǀĞƌ ;DͿ͘ dŚĞ ĚĞŶƐŝƟĞƐ ;ŶƵŵďĞƌ ŽĨ ŐŽůĚ
ƉĂƌƟĐůĞƐͬ ђŵϮͿ ŽĨ ĂƐƉĂƌƚĂƚĞ ĂŶĚ ŐůƵƚĂŵĂƚĞ ŐŽůĚ ƉĂƌƟĐůĞƐ ŝŶ
ĞǆĐŝƚĂƚŽƌǇŶĞƌǀĞƚĞƌŵŝŶĂůƐ͕ĚĞŶĚƌŝƟĐƐƉŝŶĞƐĂŶĚƐƚĞŵĚĞŶĚƌŝƚĞƐ
ĂŶĚ ƚŚĞ ĚĞŶƐŝƟĞƐ ŽĨ ĂƐƉĂƌƚĂƚĞ ĂŶĚ ' ŐŽůĚ ƉĂƌƟĐůĞƐ ŝŶ
ŝŶŚŝďŝƚŽƌǇ ƚĞƌŵŝŶĂůƐ͕ ǁĞƌĞ ĐĂůĐƵůĂƚĞĚ ĂƐ ĚĞƐĐƌŝďĞĚ ΀Ϯϰ΁͘ /Ŷ
ĞǆĐŝƚĂƚŽƌǇ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ ŐŽůĚ ƉĂƌƟĐůĞ ĚĞŶƐŝƟĞƐ ǁĞƌĞ
ƐĞƉĂƌĂƚĞůǇ ĚĞƚĞƌŵŝŶĞĚ ŝŶ ƚŚĞ ĐǇƚŽƐŽů ĂŶĚ ŵŝƚŽĐŚŽŶĚƌŝĂ͕
ǁŚŝůĞ ŝŶ ƚŚĞŽƚŚĞƌƟƐƐƵĞƉƌŽĮůĞƐŐŽůĚƉĂƌƟĐůĞĚĞŶƐŝƟĞƐǁĞƌĞ
ƌĞĐŽƌĚĞĚŝŶƚŚĞĐǇƚŽƐŽů͘ĂĐŬŐƌŽƵŶĚůĂďĞůůŝŶŐŽǀĞƌĞŵƉƚǇƌĞƐŝŶ
ŝŶĞĂĐŚƐĞĐƟŽŶǁĂƐƐƵďƚƌĂĐƚĞĚ͘
ǆĐŝƚĂƚŽƌǇƚĞƌŵŝŶĂůƐǁĞƌĞĚĞĮŶĞĚĂƐƚŚŽƐĞŵĂŬŝŶŐĂƐǇŵŵĞƚƌŝĐ
ƐǇŶĂƉƐĞƐ ǁŝƚŚ ĚĞŶĚƌŝƟĐ ƐƉŝŶĞƐ ĂŶĚ ĐŽŶƚĂŝŶŝŶŐ ŐůƵƚĂŵĂƚĞ
ŝŵŵƵŶŽŐŽůĚ ƉĂƌƟĐůĞƐ͘ /ŶŚŝďŝƚŽƌǇ ƚĞƌŵŝŶĂůƐ ǁĞƌĞ ĚĞĮŶĞĚ ĂƐ
ƚŚŽƐĞ ŵĂŬŝŶŐ ƐǇŵŵĞƚƌŝĐ ƐǇŶĂƉƐĞƐ ǁŝƚŚ ƐƚĞŵ ĚĞŶĚƌŝƚĞƐ Žƌ
ŐƌĂŶƵůĞ ĐĞůů ďŽĚŝĞƐ ĂŶĚ ĐŽŶƚĂŝŶŝŶŐ ' ŝŵŵƵŶŽŐŽůĚ ƉĂƌƟͲ
ĐůĞƐ͘dŚĞƌĞƐƵůƚƐǁĞƌĞƐƚĂƟƐƟĐĂůůǇĞǀĂůƵĂƚĞĚďǇĂŶŽŶͲƉĂƌĂŵĞƚͲ
ƌŝĐDĂŶŶtŚŝƚŶĞǇͲh ƚĞƐƚ͕ ƚǁŽ ƚĂŝůƐ ;^W^^Ϳ͘ĂƚĂĂƌĞŐŝǀĞŶ ĨŽƌ
ŽŶĞ ůĂďĞůůŝŶŐ ĞǆƉĞƌŝŵĞŶƚ͕ ŝŶ ǁŚŝĐŚ ƐĞĐƟŽŶƐ ĨƌŽŵ ϯ ĐŽŶƚƌŽůƐ
ĂŶĚϯǀĂůƉƌŽĂƚĞŚŝƉƉŽĐĂŵƉŝǁĞƌĞĂŶĂůǇƐĞĚ͕ďƵƚĂŶĂĚĚŝƟŽŶĂů
ůĂďĞůůŝŶŐĞǆƉĞƌŝŵĞŶƚ ĨŽƌĂƐƉĂƌƚĂƚĞͬŐůƵƚĂŵĂƚĞĂŶĚƚǁŽĞǆƉĞƌŝͲ
ŵĞŶƚƐĨŽƌĂƐƉĂƌƚĂƚĞͬ'ƉƌŽĚƵĐĞĚƐŝŵŝůĂƌƌĞƐƵůƚƐ͘
ZĞƐƵůƚƐ
dŽĚĞƚĞƌŵŝŶĞŝĨǀĂůƉƌŽĂƚĞƌĞŐƵůĂƚĞƐƚŚĞŶĞƌǀĞƚĞƌŵŝŶĂůƉŽŽůŽĨ
ĂƐƉĂƌƚĂƚĞĚŝīĞƌĞŶƚůǇĨƌŽŵƚŚĞĚĞŶĚƌŝƟĐƉŽŽů͕ǁĞƵƐĞĚǀĂƉƌŽĂƚĞ
ƚƌĞĂƚĞĚ ƌĂƚƐ ĂŶĚ ĐŽŶƚƌŽůƐ ƚŽ ƋƵĂŶƟĨǇ ĂƐƉĂƌƚĂƚĞ ŝŵŵƵŶͲ
ƌĞĂĐƟǀŝƟĞƐŝŶĞǆĐŝƚĂƚŽƌǇƚĞƌŵŝŶĂůƐ͕ŝŶŚŝďŝƚŽƌǇƚĞƌŵŝŶĂůƐ͕ĚĞŶĚƌŝƟĐ
ƐƉŝŶĞƐ ĂŶĚ ƐƚĞŵ ĚĞŶĚƌŝƚĞƐ ŝŶ ƚŚĞ ƐƚƌĂƚƵŵ ƌĂĚŝĂƚƵŵ ŽĨ ϯ
ŚŝƉƉŽĐĂŵƉƵƐ͘ Ɛ ŽďƐĞƌǀĞĚ ƉƌĞǀŝŽƵƐůǇ ŝŶ ƚŚĞ ϭ ƐƚƌĂƚƵŵ
ƌĂĚŝĂƚƵŵ΀ϭϮ͖ϭϴ΁͕ǁĞĨŽƵŶĚƚŚĂƚĂƐƉĂƌƚĂƚĞŝŵŵƵŶŽŐŽůĚƉĂƌƟĐůĞƐ
ǁĞƌĞůŽĐĂƚĞĚƚŽŐĞƚŚĞƌǁŝƚŚŐůƵƚĂŵĂƚĞŝŵŵƵŶŽŐŽůĚƉĂƌƟĐůĞƐŝŶ
ĞǆĐŝƚĂƚŽƌǇƚĞƌŵŝŶĂůƐ;&ŝŐ͘ϭͿĂŶĚƚŚĂƚƚŚĞĚĞŶƐŝƚǇŽĨŐŽůĚƉĂƌƟĐůĞƐ
ƐŝŐŶĂůůŝŶŐ ĂƐƉĂƌƚĂƚĞ ĂŶĚ ŐůƵƚĂŵĂƚĞ ǁĂƐ ŚŝŐŚĞƌ ŝŶ ĞǆĐŝƚĂƚŽƌǇ
ƚĞƌŵŝŶĂůƐƚŚĂŶŝŶƐƚĞŵĚĞŶĚƌŝƚĞƐ;&ŝŐ͘ϭͿ͘
&ŝŐƵƌĞϭ͗>ŽǁƉŽǁĞƌĞůĞĐƚƌŽŶŵŝĐƌŽŐƌĂƉŚƐŚŽǁŝŶŐĂƐƉĂƌƚĂƚĞ;ƐŵĂůůŐŽůĚƉĂƌƟĐůĞƐͿ
ĂŶĚŐůƵƚĂŵĂƚĞ;ůĂƌŐĞŐŽůĚƉĂƌƟĐůĞƐͿůĂďĞůůŝŶŐŽĨŶĞƌǀĞƚĞƌŵŝŶĂůƐ;ƚĞƌͿ͕ĚĞŶĚƌŝƟĐ
ƐƉŝŶĞƐ ;ƐƉͿ ĂŶĚ ƐƚĞŵ ĚĞŶĚƌŝƚĞƐ ;ĚĞŶĚͿ ŝŶ ƚŚĞ ϭ ƐƚƌĂƚƵŵ ƌĂĚŝĂƚƵŵ͘ ^ĐĂůĞ
ďĂƌсϯϬϬŶŵ
ŐŽůĚƉĂƌƟĐůĞƐƌĞƉƌĞƐĞŶƟŶŐĂƐƉĂƌƚĂƚĞďǇϲϴй;&ŝŐ͘ϮͿ͕ǁŚŝůĞƚŚĞ
ŐůƵƚĂŵĂƚĞůĞǀĞůǁĂƐŶŽƚƐŝŐŶŝĮĐĂŶƚůǇƌĞĚƵĐĞĚ;&ŝŐ͘ϮͿ͘dŚĞĂƌĞĂ
ŽĨ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ ǁĂƐ ŶŽƚ ĂīĞĐƚĞĚ ďǇ ǀĂůƉƌŽĂƚĞ ƚƌĞĂƚŵĞŶƚ
;Ϭ͘ϮϯцϬ͘ϬϰђŵϮ ŝŶ ƚŚĞĐŽŶƚƌŽůŐƌŽƵƉǀƐ͘Ϭ͘ϮϳцϬ͘ϬϭђŵϮ ŝŶ
ƚŚĞǀĂůƉƌŽĂƚĞƚƌĞĂƚĞĚŐƌŽƵƉ͖ĂǀĞƌĂŐĞĂƌĞĂц^D͕ŶсϯĂŶŝŵĂůƐ͖
ƉхϬ͘Ϭϱ ;DĂŶŶtŚŝƚŶĞǇͲh ƚĞƐƚ͕ ƚǁŽ ƚĂŝůƐͿͿ͘ /Ŷ ƐƚĞŵĚĞŶĚƌŝƚĞƐ͕
ŶĞŝƚŚĞƌ ĂƐƉĂƌƚĂƚĞ ŶŽƌ ŐůƵƚĂŵĂƚĞ ůĞǀĞůƐ ǁĞƌĞ ƐŝŐŶŝĮĐĂŶƚůǇ
ĐŚĂŶŐĞĚ ĂŌĞƌ ǀĂůƉƌŽĂƚĞ ƚƌĞĂƚŵĞŶƚ ;&ŝŐ͘ Ϯ&Ϳ͘ ,ŽǁĞǀĞƌ͕  ŐŽůĚ
ƉĂƌƟĐůĞĚĞŶƐŝƟĞƐ;ĂǀĞƌĂŐĞŶƵŵďĞƌŽĨŐŽůĚƉĂƌƟĐůĞƐц^D͕Ŷсϯ
ĂŶŝŵĂůƐͿŝŶĚĞŶĚƌŝƟĐƐƉŝŶĞƐƉĂƌĂůůĞůĞĚƚŚĞĐŚĂŶŐĞƐĚĞƚĞĐƚĞĚŝŶ
ƚŚĞŽƉƉŽƐŝŶŐŶĞƌǀĞƚĞƌŵŝŶĂůƐ͗ƐƉĂƌƚĂƚĞůĞǀĞůƐĚĞĐƌĞĂƐĞĚĨƌŽŵ
Ϯϵ͘ϱцϰ͘ϬŐŽůĚƉĂƌƟĐůĞƐͬђŵϮŝŶƚŚĞĐŽŶƚƌŽůŐƌŽƵƉƚŽϳ͘ϴцϮ͘Ϯ
ŐŽůĚ ƉĂƌƟĐůĞƐͬђŵϮ ŝŶ ƚŚĞ ǀĂůƉƌŽĂƚĞ ƚƌĞĂƚĞĚ ŐƌŽƵƉ ;ƉфϬ͘Ϭϱ͕
DĂŶŶtŚŝƚŶĞǇͲh ƚĞƐƚ͕ ƚǁŽ ƚĂŝůƐͿ͕ ǁŚŝůĞ ƚŚĞ ŐůƵƚĂŵĂƚĞ ůĞǀĞůƐ
ǁĞƌĞŶŽƚĂůƚĞƌĞĚďǇƚŚĞƚƌĞĂƚŵĞŶƚ ;ϯϮ͘ϰцϯ͘ϱŐŽůĚƉĂƌƟĐůĞƐͬ
ђŵϮ ŝŶ ƚŚĞ ĐŽŶƚƌŽůƐ ǀƐ͘ Ϯϳ͘ϰ ц ϭϬ͘Ϭ ŐŽůĚ ƉĂƌƟĐůĞƐͬђŵϮ ŝŶ ƚŚĞ
ǀĂůƉƌŽĂƚĞ ƚƌĞĂƚĞĚ ŐƌŽƵƉ͖ ƉхϬ͘Ϭϱ͕ DĂŶŶtŚŝƚŶĞǇͲh ƚĞƐƚ͕ ƚǁŽ
ƚĂŝůƐͿ͘/ŶĞǆĐŝƚĂƚŽƌǇŶĞƌǀĞƚĞƌŵŝŶĂůƐƚŚĞŵŝƚŽĐŚŽŶĚƌŝĂůĚĞŶƐŝƚǇŽĨ
ĂƐƉĂƌƚĂƚĞŐŽůĚƉĂƌƟĐůĞƐǁĂƐϰϮйůŽǁĞƌŝŶǀĂůƉƌŽĂƚĞƚƌĞĂƚĞĚƌĂƚƐ
ƚŚĂŶ ŝŶ ĐŽŶƚƌŽůƐ͕ ďƵƚ ƚŚŝƐ ĚŝīĞƌĞŶĐĞƐ ĚŝĚ ŶŽƚ ƌĞĂĐŚ ƐƚĂƟƐƟĐĂů
ƐŝŐŶŝĮĐĂŶĐĞ;ϯϵ͘Ϭцϳ͘ϭǀƐ͘ϮϮ͘ϲцϭϮ͘ϮŐŽůĚƉĂƌƟĐůĞƐͬђŵϮ͖ĂǀĞƌĂŐĞ
ŶƵŵďĞƌ ŽĨ ŐŽůĚ ƉĂƌƟĐůĞƐ ц ^D͕ Ŷсϯ ĂŶŝŵĂůƐ͖ ƉхϬ͘Ϭϱ͕DĂŶŶ
tŚŝƚŶĞǇͲh ƚĞƐƚ͕ ƚǁŽ ƚĂŝůƐͿ͘ dŚĞ ĚĞŶƐŝƟĞƐ ŽĨ ŐůƵƚĂŵĂƚĞ ŐŽůĚ
ƉĂƌƟĐůĞƐ͕ǁĞƌĞůĂƌŐĞůǇƵŶĐŚĂŶŐĞĚ;ϳϵ͘ϳцϲ͘ϰǀƐ͘ϲϮ͘ϭцϮϬ͘ϰŐŽůĚ
ƉĂƌƟĐůĞƐͬђŵϮ͖ ĂǀĞƌĂŐĞ ŶƵŵďĞƌ ŽĨ ŐŽůĚ ƉĂƌƟĐůĞƐ ц ^D͕ Ŷсϯ
ĂŶŝŵĂůƐ͖ƉхϬ͘Ϭϱ͕DĂŶŶtŚŝƚŶĞǇͲhƚĞƐƚ͕ƚǁŽƚĂŝůƐͿ͘ƐƌĞƉŽƌƚĞĚ
ďĞĨŽƌĞ ΀ϭϰ΁ ǁĞ ĨŽƵŶĚ ƚŚĂƚ ŝŶŚŝďŝƚŽƌǇ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ
ĐŽŶƚĂŝŶĞĚƐƚƌŽŶŐĂƐƉĂƌƚĂƚĞůĂďĞůůŝŶŐ;&ŝŐ͘ϯͿ͘>ŝŬĞŝŶĞǆĐŝƚĂƚŽƌǇ
ŶĞƌǀĞƚĞƌŵŝŶĂůƐ͕ǀĂůƉƌŽĂƚĞƌĞĚƵĐĞĚƚŚĞůĂďĞůůŝŶŐĨŽƌĂƐƉĂƌƚĂƚĞ
ŝŶ ŝŶŚŝďŝƚŽƌǇ ƚĞƌŵŝŶĂůƐ ;&ŝŐ͘ ϯͿ͘ /ŵŵƵŶŽŐŽůĚ ƋƵĂŶƟĮĐĂƟŽŶ
ƐŚŽǁĞĚ ƚŚĂƚ ŝŶ ƚŚĞƐĞ ƚĞƌŵŝŶĂůƐ ƚŚĞĚĞŶƐŝƚǇŽĨĂƐƉĂƌƚĂƚĞŐŽůĚ
ƉĂƌƟĐůĞƐǁĂƐ ƌĞĚƵĐĞĚ ďǇ ϲϱй ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ǀĂůƉƌŽĂƚĞ
ƚƌĞĂƚŵĞŶƚ͕ ǁŚŝůĞ ƚŚĞ ' ůĞǀĞů ǁĂƐ ƵŶĐŚĂŶŐĞĚ ;ƉхϬ͘Ϭϱ͕
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&RQWURO9DOSURDWH&RQWURO9DOSURDWH
$VSDUWDWH*OXWDPDWH
)LJXUH9DOSURDWHUHGXFHVWKHOHYHORIWKHH[FLWDWRU\DPLQRDFLGDVSDUWDWHLQH[FLWDWRU\QHUYHWHUPLQDOV(OHFWURQPLFURJUDSKVVKRZLQJDVSDUWDWHVPDOOJROG
SDUWLFOHVDQGJOXWDPDWHODUJHJROGSDUWLFOHV ODEHOOLQJRIQHUYHWHUPLQDOVWHUPDNLQJDV\PPHWULFV\QDSVHVZLWKGHQGULWLFVSLQHVVS$DQG&DQGRIVWHP
GHQGULWHVGHQG%DQG' LQ WKHVWUDWXPUDGLDWXPRI&$KLSSRFDPSXVIURPVDOLQH WUHDWHGFRQWUROV$DQG%DQGYDOSURDWH WUHDWHGUDWV&DQG'6FDOH
EDUV QP4XDQWLWDWLYHDVVHVVPHQWRI DVSDUWDWHDQGJOXWDPDWH LQ H[FLWDWRU\ WHUPLQDOV (DQG VWHPGHQGULWHV )7KH YDOXHV LQGLFDWHGE\ WKHEDU FKDUWV
DUHPHDQQXPEHURIJROGSDUWLFOHVP6(0RIQ UDWVH[FLWDWRU\WHUPLQDOVVWHPGHQGULWHVSHUDQLPDO$VSDUWDWHYDOXHVLQYDOSURDWHWUHDWHG
WHUPLQDOVZHUHVLJQL¿FDQWO\ORZHUWKDQWKHYDOXHVLQFRQWUROWHUPLQDOVS0DQQ:KLWQH\8WHVWWZRWDLOV63667KHJOXWDPDWHYDOXHV
LQFRQWUROWHUPLQDOVDQGYDOSURDWHWUHDWHGWHUPLQDOVDVZHOODVDVSDUWDWHDQGJOXWDPDWHYDOXHVLQVWHPGHQGULWHVDQG
LQFRQWUROVYVDQGLQYDOSURDWHWUHDWHGDQLPDOVZHUHQRWVLJQL¿FDQWO\DOWHUHGE\YDOSURDWHWUHDWPHQWS!0DQQ:KLWQH\8WHVWWZRWDLOV
6366
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ĨŽƌ ƉĂƌƚ ŽĨ ƚŚĞ ĂŶƟĞƉŝůĞƉƟĐ Žƌ ŵŽŽĚ ƐƚĂďŝůŝǌŝŶŐ ĞīĞĐƚ ŽĨ
ǀĂůƉƌŽĂƚĞ͘/ŶƚĞƌĞƐƟŶŐůǇ͕ ďǇĞůĞĐƚƌŽƉŚǇƐŝŽůŽŐǇŝƚŚĂƐďĞĞŶĨŽƵŶĚ
ƚŚĂƚ ǀĂůƉƌŽĂƚĞ ĚĞĐƌĞĂƐĞƐ ED ƌĞĐĞƉƚŽƌ ƌĞƐƉŽŶƐĞƐ ǀŝĂ Ă
ƉƌĞͲƐǇŶĂƉƟĐ ŵĞĐŚĂŶŝƐŵ ΀ϳ͖ϭϬ΁͘ &ƵƌƚŚĞƌ ƐƵƉƉŽƌƟŶŐ ƚŚĞ ŝĚĞĂ
ƚŚĂƚ ǀĂůƉƌŽĂƚĞ ƚĂƌŐĞƚƐ ĂƐƉĂƌƚĂƚĞ ƌĞůĞĂƐĞ͕ ŝƐ ƚŚĂƚ ǀĂůƉƌŽĂƚĞ
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ϴϬ
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&ŝŐƵƌĞ ϯ͗ dŚĞ ůĞǀĞů ŽĨ ƚŚĞ ĞǆĐŝƚĂƚŽƌǇ ĂŵŝŶŽ ĂĐŝĚ ĂƐƉĂƌƚĂƚĞ ŝƐ ƌĞĚƵĐĞĚ ŝŶ
ŝŶŚŝďŝƚŽƌǇ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ ĂŌĞƌ ǀĂůƉƌŽĂƚĞ ƚƌĞĂƚŵĞŶƚ͘ ůĞĐƚƌŽŶ ŵŝĐƌŽŐƌĂƉŚƐ
ƐŚŽǁŝŶŐ ĂƐƉĂƌƚĂƚĞ ;ƐŵĂůů ŐŽůĚ ƉĂƌƟĐůĞƐͿ ĂŶĚ ' ;ůĂƌŐĞ ŐŽůĚ ƉĂƌƟĐůĞƐͿ
ůĂďĞůůŝŶŐ ŝŶ ŝŶŚŝďŝƚŽƌǇ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ ;ƚĞƌͿ ŽŶ ŐƌĂŶƵůĞ ĐĞůů ďŽĚŝĞƐ ;'Ϳ ŝŶ ƚŚĞ
ϯŚŝƉƉŽĐĂŵƉƵƐĨƌŽŵĂƐĂůŝŶĞƚƌĞĂƚĞĚ;ĐŽŶƚƌŽůͿ;ͿĂŶĚĂǀĂůƉƌŽĂƚĞƚƌĞĂƚĞĚ
ƌĂƚ;Ϳ͘^ĐĂůĞďĂƌƐсϭϬϬŶŵ͘YƵĂŶƟƚĂƟǀĞĂƐƐĞƐƐŵĞŶƚŽĨĂƐƉĂƌƚĂƚĞĂŶĚ'ŝŶ
ŝŶŚŝďŝƚŽƌǇ ƚĞƌŵŝŶĂůƐ ;Ϳ͘ dŚĞ ǀĂůƵĞƐ ŝŶĚŝĐĂƚĞĚ ďǇ ƚŚĞ ďĂƌ ĐŚĂƌƚƐ ĂƌĞ ŵĞĂŶ
ŶƵŵďĞƌ ŽĨ ŐŽůĚ ƉĂƌƟĐůĞƐͬђŵϮц ^D ŝŶ Ŷсϯ ƌĂƚƐ ;ϮϬͲϮϱ ƚĞƌŵŝŶĂůƐ ĨƌŽŵĞĂĐŚ
ĂŶŝŵĂůǁĞƌĞĂŶĂůǇƐĞĚͿ͘ΎƐƉĂƌƚĂƚĞǀĂůƵĞƐŝŶǀĂůƉƌŽĂƚĞƚƌĞĂƚĞĚƚĞƌŵŝŶĂůƐ;Ϯϰ͘ϱ
цϱ͘ϮͿǁĞƌĞƐŝŐŶŝĮĐĂŶƚůǇůŽǁĞƌƚŚĂŶƚŚĞǀĂůƵĞƐŝŶĐŽŶƚƌŽůƚĞƌŵŝŶĂůƐ;ϲϯ͘ϳцϭϮ͘Ϭ͖
ƉфϬ͘Ϭϱ͕DĂŶŶtŚŝƚŶĞǇͲhƚĞƐƚ͕ƚǁŽƚĂŝůƐ;^W^^ͿͿ͕ǁŚŝůĞ'ǀĂůƵĞƐŝŶĐŽŶƚƌŽů
ƚĞƌŵŝŶĂůƐ;ϮϮ͘Ϭцϲ͘ϰϬͿĂŶĚǀĂůƉƌŽĂƚĞƚƌĞĂƚĞĚƚĞƌŵŝŶĂůƐ;Ϯϴ͘ϬцϮ͘ϮϲͿǁĞƌĞŶŽƚ
ƐŝŐŶŝĮĐĂŶƚůǇĚŝīĞƌĞŶƚ;ƉхϬ͘Ϭϱ͕DĂŶŶtŚŝƚŶĞǇͲhƚĞƐƚ͕ƚǁŽƚĂŝůƐ;^W^^ͿͿ͘
ŝŶ ŝŶŚŝďŝƚŽƌǇ ƚĞƌŵŝŶĂůƐ ǁĂƐ ĂƉƉƌŽǆŝŵĂƚĞůǇ ƚǁŝĐĞ ŽĨ ƚŚĂƚ ŝŶ
ĞǆĐŝƚĂƚŽƌǇƚĞƌŵŝŶĂůƐ͘dŚŝƐŝƐŝŶĂŐƌĞĞŵĞŶƚǁŝƚŚƐĞǀĞƌĂůƐƚƵĚŝĞƐ
ƐŚŽǁŝŶŐ ŚŝŐŚĞƌ ĂƐƉĂƌƚĂƚĞ ůĞǀĞůƐ ŝŶ 'ĞƌŐŝĐ ŶĞƵƌŽŶƐ ƚŚĂŶ
ŝŶ ŐůƵƚĂŵĂƚĞƌŐŝĐ ŶĞƵƌŽŶƐ ΀ϭϯ͖ϭϯ͖ϭϱ͖ϭϱ΁͕ ĂŶĚƉƌŽďĂďůǇ ŚĂǀĞ Ă
ŵĞƚĂďŽůŝĐ ĞǆƉůĂŶĂƟŽŶ͗ KŶĞ ŽĨ ƚŚĞ ƌĂƚĞ ůŝŵŝƟŶŐ ĞŶǌǇŵĞƐ ŽĨ
ƚŚĞ ŽǆŝĚĂƟǀĞ ŵĞƚĂďŽůŝƐŵ ŝƐ ɲͲŬĞƚŽŐůƵƚĂƌĂƚĞ ĚĞŚǇĚƌŽŐĞŶĂƐĞ
΀Ϯϯ͖ϯϰ΁͘/Ŷ'ĞƌŐŝĐŶĞƵƌŽŶƐ͕ƚŚĞ'ͲƐŚƵŶƚĐĂŶĐŝƌĐƵŵǀĞŶƚ
 ƚŚĞ ƐƚĞƉ ĐĂƚĂůǇǌĞĚ ďǇ ɲͲŬĞƚŽŐůƵƚĂƌĂƚĞ͕ ĨĂĐŝůŝƚĂƟŶŐ ƚŚĞ ŇƵǆ
ƚŚƌŽƵŐŚ ƚŽ ŽǆĂůŽĂĐĞƚĂƚĞ͘ dŚĞ ĐŽŶǀĞƌƐŝŽŶ ŽĨ ŽǆĂůŽĂĐĞƚĂƚĞ
ƚŽ ĐŝƚƌĂƚĞ͕ ŚŽǁĞǀĞƌ͕  ŝƐ ĚĞƉĞŶĚĞŶƚ ŽĨ ĂĐĞƚǇůͲŽ ĨŽƌŵĞĚ ďǇ
ƉǇƌƵǀĂƚĞĚĞŚǇĚƌŽŐĞŶĂƐĞ͕ǁŚŽƐĞĐĂƉĂĐŝƚǇ ŝƐĂƐ ůŝŵŝƚĞĚĂƐƚŚĂƚ
ŽĨɲͲŬĞƚŽŐůƵƚĂƌĂƚĞĚĞŚǇĚƌŽŐĞŶĂƐĞ΀ϯϰ΁͘dŚƵƐŽǆĂůŽĂĐĞƚĂƚĞ͕ĂŶĚ
ƐƵďƐĞƋƵĞŶƚůǇĂƐƉĂƌƚĂƚĞ͕ĂĐĐƵŵƵůĂƚĞƐŝŶƚŚĞƐĞŶĞƵƌŽŶƐ͘

/ŶĐŽŶĐůƵƐŝŽŶ͕ǁĞƐŚŽǁƚŚĂƚǀĂůƉƌŽĂƚĞůĞĂĚƐƚŽĂĚĞĐƌĞĂƐĞŝŶƚŚĞ
ŶĞƌǀĞƚĞƌŵŝŶĂůĐŽŶƚĞŶƚŽĨƚŚĞĞǆĐŝƚĂƚŽƌǇĂŵŝŶŽĂĐŝĚĂƐƉĂƌƚĂƚĞ
ŝŶŚŝƉƉŽĐĂŵƉƵƐ͕ƐƵŐŐĞƐƟŶŐƚŚĂƚǀĂůƉƌŽĂƚĞĂĐƚƐƚŚƌŽƵŐŚƌĞĚƵĐŝŶŐ
EDƌĞĐĞƉƚŽƌŵĞĚŝĂƚĞĚĞǆĐŝƚĂƚŽƌǇƐŝŐŶĂůůŝŶŐŝŶƚŚĞďƌĂŝŶ͘
ZĞĨĞƌĞŶĐĞƐ
 ΀ϭ΁ >͘ĂƫƐƟŶ͕D͘sĂƌŽƩŽ͕'͘ĞƌůĞƐĞ͕'͘ZŽŵĂŶ͕
īĞĐƚƐŽĨƐŽŵĞĂŶƟĐŽŶǀƵůƐĂŶƚĚƌƵŐƐŽŶďƌĂŝŶ'ůĞǀĞůĂŶĚ
'ĂŶĚ'ͲdĂĐƟǀŝƟĞƐ͕EĞƵƌŽĐŚĞŵ͘ZĞƐ͘ϵ;ϭϵϴϰͿϮϮϱͲ
Ϯϯϭ͘
 ΀Ϯ΁ >͘,͘ĞƌŐĞƌƐĞŶ͕:͘^ƚŽƌŵͲDĂƚŚŝƐĞŶ͕
s͘'ƵŶĚĞƌƐĞŶ͕/ŵŵƵŶŽŐŽůĚƋƵĂŶƟĮĐĂƟŽŶŽĨĂŵŝŶŽĂĐŝĚƐĂŶĚ
ƉƌŽƚĞŝŶƐŝŶĐŽŵƉůĞǆƐƵďĐĞůůƵůĂƌĐŽŵƉĂƌƚŵĞŶƚƐ͕EĂƚ͘WƌŽƚŽĐ͘ϯ
;ϮϬϬϴͿϭϰϰͲϭϱϮ͘
 ΀ϯ΁ ͘^͘ŝŐŐƐ͕͘Z͘WĞĂƌĐĞ͕>͘:͘&ŽǁůĞƌ͕ W͘ ^͘tŚŝƩŽŶ͕
dŚĞĞīĞĐƚŽĨƐŽĚŝƵŵǀĂůƉƌŽĂƚĞŽŶĞǆƚƌĂĐĞůůƵůĂƌ'ĂŶĚ
ŽƚŚĞƌĂŵŝŶŽĂĐŝĚƐŝŶƚŚĞƌĂƚǀĞŶƚƌĂůŚŝƉƉŽĐĂŵƉƵƐ͗ĂŶŝŶǀŝǀŽ
ŵŝĐƌŽĚŝĂůǇƐŝƐƐƚƵĚǇ͕ ƌĂŝŶZĞƐ͘ϱϵϰ;ϭϵϵϮͿϭϯϴͲϭϰϮ͘
 ΀ϰ΁ :͘ƌŽŵĂŶ͕^͘ŶĚĞƌƐŽŶ͕K͘W͘KƩĞƌƐĞŶ͕ŶƌŝĐŚͲ
ŵĞŶƚŽĨŐůƵƚĂŵĂƚĞͲůŝŬĞŝŵŵƵŶŽƌĞĂĐƟǀŝƚǇŝŶƉƌŝŵĂƌǇĂīĞƌĞŶƚ
ƚĞƌŵŝŶĂůƐƚŚƌŽƵŐŚŽƵƚƚŚĞƐƉŝŶĂůĐŽƌĚĚŽƌƐĂůŚŽƌŶ͕Ƶƌ͘ :͘EĞƵͲ
ƌŽƐĐŝ͘ϱ;ϭϵϵϯͿϭϬϱϬͲϭϬϲϭ͘
 ΀ϱ΁ ͘'͘ŚĂƉŵĂŶ͕<͘ZŝůĞǇ͕ D͘͘ǀĂŶƐ͕
͘^͘DĞůĚƌƵŵ͕ĐƵƚĞĞīĞĐƚƐŽĨƐŽĚŝƵŵǀĂůƉƌŽĂƚĞĂŶĚŐĂŵŵĂͲ
ǀŝŶǇů'ŽŶƌĞŐŝŽŶĂůĂŵŝŶŽĂĐŝĚŵĞƚĂďŽůŝƐŵŝŶƚŚĞƌĂƚďƌĂŝŶ͗
ŝŶĐŽƌƉŽƌĂƟŽŶŽĨϮͲ΀ϭϰ΁ŐůƵĐŽƐĞŝŶƚŽĂŵŝŶŽĂĐŝĚƐ͕EĞƵƌŽĐŚĞŵ͘
ZĞƐ͘ϳ;ϭϵϴϮͿϭϬϴϵͲϭϭϬϱ͘
 ΀ϲ΁ :͘D͘ƌŽǁĚĞƌ͕ ,͘&͘ ƌĂĚĨŽƌĚ͕ŽŵŵŽŶĂŶƟͲ
ĐŽŶǀƵůƐĂŶƚƐŝŶŚŝďŝƚĂϮнƵƉƚĂŬĞĂŶĚĂŵŝŶŽĂĐŝĚŶĞƵƌŽƚƌĂŶƐͲ
ŵŝƩĞƌƌĞůĞĂƐĞŝŶǀŝƚƌŽ͕ƉŝůĞƉƐŝĂϮϴ;ϭϵϴϳͿϯϳϴͲϯϴϮ͘
 ΀ϳ΁ D͘K͘ƵŶŶŝŶŐŚĂŵ͕'͘>͘tŽŽĚŚĂůů͕Z͘^͘:ŽŶĞƐ͕
sĂůƉƌŽĂƚĞŵŽĚŝĮĞƐƐƉŽŶƚĂŶĞŽƵƐĞǆĐŝƚĂƟŽŶĂŶĚŝŶŚŝďŝƟŽŶĂƚ
ĐŽƌƟĐĂůƐǇŶĂƉƐĞƐŝŶǀŝƚƌŽ͕EĞƵƌŽƉŚĂƌŵĂĐŽůŽŐǇϰϱ;ϮϬϬϯͿϵϬϳͲ
ϵϭϳ͘
 ΀ϴ΁ D͘͘ƵƌƌĂƐ͕Z͘ŝŶŐůĞĚŝŶĞ͕^ĞůĞĐƟǀŝƚǇŽĨ
ĂŵŝŶŽĂĐŝĚƚƌĂŶƐŵŝƩĞƌƐĂĐƟŶŐĂƚEͲŵĞƚŚǇůͲͲĂƐƉĂƌƚĂƚĞĂŶĚ
ĂŵŝŶŽͲϯͲŚǇĚƌŽǆǇͲϱͲŵĞƚŚǇůͲϰͲŝƐŽǆĂǌŽůĞƉƌŽƉŝŽŶĂƚĞƌĞĐĞƉƚŽƌƐ͕
DŽů͘WŚĂƌŵĂĐŽů͘ϰϭ;ϭϵϵϮͿϱϮϬͲϱϮϲ͘
 ΀ϵ΁ ͘ŶŐĞůƐĞŶ͕͘tĞƐƚĞƌďĞƌŐ͕&͘ &ŽŶŶƵŵ͕
d͘tŝĞůŽĐŚ͕īĞĐƚŽĨŝŶƐƵůŝŶͲŝŶĚƵĐĞĚŚǇƉŽŐůǇĐĞŵŝĂŽŶƚŚĞĐŽŶͲ
ĐĞŶƚƌĂƟŽŶƐŽĨŐůƵƚĂŵĂƚĞĂŶĚƌĞůĂƚĞĚĂŵŝŶŽĂĐŝĚƐĂŶĚĞŶĞƌŐǇ
ŵĞƚĂďŽůŝƚĞƐŝŶƚŚĞŝŶƚĂĐƚĂŶĚĚĞĐŽƌƟĐĂƚĞĚƌĂƚŶĞŽƐƚƌŝĂƚƵŵ͕:͘
EĞƵƌŽĐŚĞŵ͘ϰϳ;ϭϵϴϲͿϭϲϯϰͲϭϲϰϭ͘
 ΀ϭϬ΁ '͘'Žďďŝ͕>͘:ĂŶŝƌŝ͕^ŽĚŝƵŵͲĂŶĚŵĂŐŶĞƐŝƵŵͲ
ǀĂůƉƌŽĂƚĞŝŶǀŝǀŽŵŽĚƵůĂƚĞŐůƵƚĂŵĂƚĞƌŐŝĐĂŶĚ'ĞƌŐŝĐ
ƐǇŶĂƉƐĞƐŝŶƚŚĞŵĞĚŝĂůƉƌĞĨƌŽŶƚĂůĐŽƌƚĞǆ͕WƐǇĐŚŽƉŚĂƌŵĂĐŽůŽŐǇ
;ĞƌůͿϭϴϱ;ϮϬϬϲͿϮϱϱͲϮϲϮ͘
 ΀ϭϭ΁ z͘'ŽĚŝŶ͕>͘,ĞŝŶĞƌ͕ :͘DĂƌŬ͕W͘DĂŶĚĞů͕īĞĐƚƐ
ŽĨ/ͲŶͲƉƌŽƉǇůĂĐĞƚĂƚĞ͕ĂŶĚĂŶƟĐŽŶǀƵůƐŝǀĞĐŽŵƉŽƵŶĚ͕ŽŶ'
ŵĞƚĂďŽůŝƐŵ͕:͘EĞƵƌŽĐŚĞŵ͘ϭϲ;ϭϵϲϵͿϴϲϵͲϴϳϯ͘

ŝŶŚŝďŝƚƐƚŚĞŝŶĐƌĞĂƐĞĚĂƐƉĂƌƚĂƚĞƌĞůĞĂƐĞĂŶĚƐĞŝǌƵƌĞƐŬŶŽǁŶƚŽ
ŽĐĐƵƌ ŝŶĞƉŝůĞƉƟĐůͲŵŝĐĞ ΀ϭϳ΁͘ůƐŽ͕ ŝŶƉĞŶƚǇůĞŶĞƚĞƚƌĂǌŽů ŬŝŶͲ
ĚůĞĚƌĂƚƐ͕ĂƐƉĂƌƚĂƚĞƌĞůĞĂƐĞĚƵƌŝŶŐƐĞŝǌƵƌĞƐ ŝƐ ƌĞĚƵĐĞĚďǇǀĂůͲ
ƉƌŽĂƚĞ΀Ϯϱ΁͘
tŚĂƚ ŝƐ ƚŚĞ ŵĞĐŚĂŶŝƐŵ ĨŽƌ ƚŚĞ ǀĂůƉƌŽĂƚĞ ŝŶĚƵĐĞĚ ĚĞĐƌĞĂƐĞ
ŝŶ ŶĞƌǀĞ ƚĞƌŵŝŶĂů ĂƐƉĂƌƚĂƚĞ͍ sĂůƉƌŽĂƚĞ ŝŶŚŝďŝƚƐ ƚŚĞ ŝŶƚƌĂͲ
ŵŝƚŽĐŚŽŶĚƌŝĂů ĞŶǌǇŵĞ ɲͲŬĞƚŽŐůƵƚĂƌĂƚĞ ĚĞŚǇĚƌŽŐĞŶĂƐĞ ΀ϮϬ΁͕
ǁŚŝĐŚ ůĞĂĚƐ ƚŽ ƌĞĚƵĐĞĚ ĐŽŶĐĞŶƚƌĂƟŽŶ ŽĨ ŽǆĂůŽĂĐĞƚĂƚĞ ĂŶĚ
ƚŚĞƌĞďǇ ŽĨ ĂƐƉĂƌƚĂƚĞ͕ ǁŚŝĐŚ ŝƐ ĨŽƌŵĞĚ ĨƌŽŵ ŽǆĂůŽĂĐĞƚĂƚĞ ǀŝĂ
ƚŚĞ ĂƐƉĂƌƚĂƚĞ ĂŵŝŶŽƚƌĂŶƐĨĞƌĂƐĞ ƌĞĂĐƟŽŶ͘ dŚĞ ƐĞůĞĐƟǀĞ ĞīĞĐƚ
ŝŶ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ ŵŝŐŚƚ ďĞ ĚƵĞ ƚŽ Ă ŚŝŐŚĞƌ ƚƵƌŶŽǀĞƌ ŽĨ
ƚƌĂŶƐŵŝƩĞƌ ĂŵŝŶŽ ĂĐŝĚƐ ŝŶ ŶĞƌǀĞ ƚĞƌŵŝŶĂůƐ ƚŚĂŶ ŝŶ ƐŽŵĂƚŽͲ
ĚĞŶĚƌŝƟĐĐŽŵƉĂƌƚŵĞŶƚƐ΀ϵ΁͘
/ƚƐŚŽƵůĚĂůƐŽďĞŶŽƚĞĚƚŚĂƚƚŚĞůĂďĞůůŝŶŐĚĞŶƐŝƚǇŽĨĂƐƉĂƌƚĂƚĞ
 ΀Ϯϳ΁ t͘>ƂƐĐŚĞƌ͕ sĂůƉƌŽĂƚĞ͗ĂƌĞĂƉƉƌĂŝƐĂůŽĨŝƚƐ
ƉŚĂƌŵĂĐŽĚǇŶĂŵŝĐƉƌŽƉĞƌƟĞƐĂŶĚŵĞĐŚĂŶŝƐŵƐŽĨĂĐƟŽŶ͕WƌŽŐ͘
EĞƵƌŽďŝŽů͘ϱϴ;ϭϵϵϵͿϯϭͲϱϵ͘
 ΀Ϯϴ΁ t͘>ŽƐĐŚĞƌ͕ ͘,ŽƌƐƚĞƌŵĂŶŶ͕ŝīĞƌĞŶƟĂůĞĨͲ
ĨĞĐƚƐŽĨǀŝŐĂďĂƚƌŝŶ͕ŐĂŵŵĂͲĂĐĞƚǇůĞŶŝĐ'͕ĂŵŝŶŽŽǆǇĂĐĞƟĐ
ĂĐŝĚ͕ĂŶĚǀĂůƉƌŽĂƚĞŽŶůĞǀĞůƐŽĨǀĂƌŝŽƵƐĂŵŝŶŽĂĐŝĚƐŝŶƌĂƚďƌĂŝŶ
ƌĞŐŝŽŶƐĂŶĚƉůĂƐŵĂ͕EĂƵŶǇŶ^ĐŚŵŝĞĚĞďĞƌŐƐƌĐŚ͘WŚĂƌŵĂĐŽů͘
ϯϰϵ;ϭϵϵϰͿϮϳϬͲϮϳϴ͘ 
 ΀Ϯϵ΁ t͘>ŽƐĐŚĞƌ͕ D͘sĞƩĞƌ͕ ƌƵŐͲŝŶĚƵĐĞĚĐŚĂŶŐĞƐ
ŝŶ'ĐŽŶƚĞŶƚŽĨŶĞƌǀĞĞŶĚŝŶŐƐŝŶϭϭƌĂƚďƌĂŝŶƌĞŐŝŽŶƐ͘Žƌ
ƌĞůĂƟŽŶƚŽƉŚĂƌŵĂĐŽůŽŐŝĐĂůĞīĞĐƚƐ͕EĞƵƌŽƐĐŝ͘>ĞƩ͘ϰϳ;ϭϵϴϰͿ
ϯϮϱͲϯϯϭ͘
 ΀ϯϬ΁ Z͘>͘DĂĐĚŽŶĂůĚ͕'͘<͘ĞƌŐĞǇ͕ sĂůƉƌŽŝĐĂĐŝĚ
ĂƵŐŵĞŶƚƐ'ͲŵĞĚŝĂƚĞĚƉŽƐƚƐǇŶĂƉƟĐŝŶŚŝďŝƟŽŶŝŶĐƵůƚƵƌĞĚ
ŵĂŵŵĂůŝĂŶŶĞƵƌŽŶƐ͕ƌĂŝŶZĞƐ͘ϭϳϬ;ϭϵϳϵͿϱϱϴͲϱϲϮ͘
 ΀ϯϭ΁ Z͘>͘DĂĐĚŽŶĂůĚ͕D͘:͘DĐ>ĞĂŶ͕ŶƟĐŽŶǀƵůƐĂŶƚ
ĚƌƵŐƐ͗ŵĞĐŚĂŶŝƐŵƐŽĨĂĐƟŽŶ͕Ěǀ͘ EĞƵƌŽů͘ϰϰ;ϭϵϴϲͿϳϭϯͲϳϯϲ͘
 ΀ϯϮ΁ ͘DŽŶƟ͕͘WŽůĂǌǌŝ͕͘ŽŶƚĞƐƚĂďŝůĞ͕ŝŽĐŚĞŵŝͲ
ĐĂů͕ŵŽůĞĐƵůĂƌĂŶĚĞƉŝŐĞŶĞƟĐŵĞĐŚĂŶŝƐŵƐŽĨǀĂůƉƌŽŝĐĂĐŝĚ
ŶĞƵƌŽƉƌŽƚĞĐƟŽŶ͕Ƶƌƌ͘ DŽů͘WŚĂƌŵĂĐŽů͘Ϯ;ϮϬϬϵͿϵϱͲϭϬϵ͘
 ΀ϯϯ΁ ͘DŽƌůĂŶĚ͕<͘͘ŽůĚŝŶŐŚ͕͘'͘/ǀĞƌƐĞŶ͕
͘,ĂƐƐĞů͕sĂůƉƌŽĂƚĞŝƐŶĞƵƌŽƉƌŽƚĞĐƟǀĞĂŐĂŝŶƐƚŵĂůŽŶĂƚĞ
ƚŽǆŝĐŝƚǇŝŶƌĂƚƐƚƌŝĂƚƵŵ͗ĂŶĂƐƐŽĐŝĂƟŽŶǁŝƚŚĂƵŐŵĞŶƚĂƟŽŶŽĨ
ŚŝŐŚͲĂĸŶŝƚǇŐůƵƚĂŵĂƚĞƵƉƚĂŬĞ͕:͘ĞƌĞď͘ůŽŽĚ&ůŽǁDĞƚĂďϮϰ
;ϮϬϬϰͿϭϮϮϲͲϭϮϯϰ͘
 ΀ϯϰ΁ ͘DŽƌůĂŶĚ͕^͘,ĞŶũƵŵ͕͘'͘/ǀĞƌƐĞŶ͕
<͘<͘^ŬƌĞĚĞ͕͘,ĂƐƐĞů͕ǀŝĚĞŶĐĞĨŽƌĂŚŝŐŚĞƌŐůǇĐŽůǇƟĐƚŚĂŶŽǆŝͲ
ĚĂƟǀĞŵĞƚĂďŽůŝĐĂĐƟǀŝƚǇŝŶǁŚŝƚĞŵĂƩĞƌŽĨƌĂƚďƌĂŝŶ͕EĞƵƌŽͲ
ĐŚĞŵ͘/Ŷƚ͘ϱϬ;ϮϬϬϳͿϳϬϯͲϳϬϵ͘
 ΀ϯϱ΁ :͘s͘ EĂĚůĞƌ͕ ƐƉĂƌƚĂƚĞƌĞůĞĂƐĞĂŶĚƐŝŐŶĂůůŝŶŐŝŶ
ƚŚĞŚŝƉƉŽĐĂŵƉƵƐ͕EĞƵƌŽĐŚĞŵ͘ZĞƐ͘ϯϲ;ϮϬϭϭͿϲϲϴͲϲϳϲ͘
΀ ΀ϯϲ΁ K͘W͘KƩĞƌƐĞŶ͕WŽƐƚĞŵďĞĚĚŝŶŐůŝŐŚƚͲĂŶĚ
ĞůĞĐƚƌŽŶŵŝĐƌŽƐĐŽƉŝĐŝŵŵƵŶŽĐǇƚŽĐŚĞŵŝƐƚƌǇŽĨĂŵŝŶŽĂĐŝĚƐ͗
ĚĞƐĐƌŝƉƟŽŶŽĨĂŶĞǁŵŽĚĞůƐǇƐƚĞŵĂůůŽǁŝŶŐŝĚĞŶƟĐĂůĐŽŶĚŝͲ
ƟŽŶƐĨŽƌƐƉĞĐŝĮĐŝƚǇƚĞƐƟŶŐĂŶĚƟƐƐƵĞƉƌŽĐĞƐƐŝŶŐ͕ǆƉ͘ƌĂŝŶ
ZĞƐ͘ϲϵ;ϭϵϴϳͿϭϲϳͲϭϳϰ͘
 ΀ϯϳ΁ K͘W͘KƩĞƌƐĞŶ͕E͘ŚĂŶŐ͕&͘tĂůďĞƌŐ͕DĞƚĂďŽůŝĐ
ĐŽŵƉĂƌƚŵĞŶƚĂƟŽŶŽĨŐůƵƚĂŵĂƚĞĂŶĚŐůƵƚĂŵŝŶĞ͗ŵŽƌƉŚŽůŽŐŝĐĂů
ĞǀŝĚĞŶĐĞŽďƚĂŝŶĞĚďǇƋƵĂŶƟƚĂƟǀĞŝŵŵƵŶŽĐǇƚŽĐŚĞŵŝƐƚƌǇŝŶ
ƌĂƚĐĞƌĞďĞůůƵŵ͕EĞƵƌŽƐĐŝĞŶĐĞϰϲ;ϭϵϵϮͿϱϭϵͲϱϯϰ͘
 ΀ϯϴ΁ '͘ZŽƐĞŶďĞƌŐ͕dŚĞŵĞĐŚĂŶŝƐŵƐŽĨĂĐƟŽŶŽĨ
ǀĂůƉƌŽĂƚĞŝŶŶĞƵƌŽƉƐǇĐŚŝĂƚƌŝĐĚŝƐŽƌĚĞƌƐ͗ĐĂŶǁĞƐĞĞƚŚĞĨŽƌĞƐƚ
ĨŽƌƚŚĞƚƌĞĞƐ͍͕ĞůůDŽů͘>ŝĨĞ^Đŝ͘ϲϰ;ϮϬϬϳͿϮϬϵϬͲϮϭϬϯ͘
 ΀ϯϵ΁ W͘ :͘^ĐŚĞĐŚƚĞƌ͕ z͘dƌĂŶŝĞƌ͕ :͘'ƌŽǀĞ͕īĞĐƚŽĨŶͲ
ĚŝƉƌŽƉǇůĂĐĞƚĂƚĞŽŶĂŵŝŶŽĂĐŝĚĐŽŶĐĞŶƚƌĂƟŽŶƐŝŶŵŽƵƐĞďƌĂŝŶ͗
ĐŽƌƌĞůĂƟŽŶƐǁŝƚŚĂŶƟͲĐŽŶǀƵůƐĂŶƚĂĐƟǀŝƚǇ͕ :͘EĞƵƌŽĐŚĞŵ͘ϯϭ
;ϭϵϳϴͿϭϯϮϱͲϭϯϮϳ͘
 ΀ϰϬ΁ ^͘D͘^ƚĂŚů͕ŶƟĐŽŶǀƵůƐĂŶƚƐĂƐŵŽŽĚƐƚĂďŝůŝǌͲ
ĞƌƐĂŶĚĂĚũƵŶĐƚƐƚŽĂŶƟƉƐǇĐŚŽƟĐƐ͗ǀĂůƉƌŽĂƚĞ͕ůĂŵŽƚƌŝŐŝŶĞ͕ĐĂƌͲ
ďĂŵĂǌĞƉŝŶĞ͕ĂŶĚŽǆĐĂƌďĂǌĞƉŝŶĞĂŶĚĂĐƟŽŶƐĂƚǀŽůƚĂŐĞͲŐĂƚĞĚ
ƐŽĚŝƵŵĐŚĂŶŶĞůƐ͕:͘ůŝŶ͘WƐǇĐŚŝĂƚƌǇϲϱ;ϮϬϬϰͿϳϯϴͲϳϯϵ͘
 ΀ϰϭ΁ z͘dĂŬƵŵŝ͕͘DĂƚƐƵďĂƌĂ͕͘ZŝŶǀŝŬ͕
K͘W͘KƩĞƌƐĞŶ͕dŚĞĂƌƌĂŶŐĞŵĞŶƚŽĨŐůƵƚĂŵĂƚĞƌĞĐĞƉƚŽƌƐŝŶĞǆĐŝͲ
ƚĂƚŽƌǇƐǇŶĂƉƐĞƐ͕ŶŶ͘E͘z͘ ĐĂĚ͘^Đŝ͘ϴϲϴ;ϭϵϵϵͿϰϳϰͲϰϴϮ͘
 ΀ϰϮ΁ E͘Z͘tŝůƐŽŶ͕:͘<ĂŶŐ͕͘s͘ ,ƵĞƐŬĞ͕d͘ >ĞƵŶŐ͕
,͘sĂƌŽƋƵŝ͕:͘'͘DƵƌŶŝĐŬ͕:͘͘ƌŝĐŬƐŽŶ͕'͘>ŝƵ͕WƌĞƐǇŶĂƉƟĐƌĞŐƵůĂͲ
ƟŽŶŽĨƋƵĂŶƚĂůƐŝǌĞďǇƚŚĞǀĞƐŝĐƵůĂƌŐůƵƚĂŵĂƚĞƚƌĂŶƐƉŽƌƚĞƌ
s'>hdϭ͕:͘EĞƵƌŽƐĐŝ͘Ϯϱ;ϮϬϬϱͿϲϮϮϭͲϲϮϯϰ͘
 ΀ϭϮ΁ s͘'ƵŶĚĞƌƐĞŶ͕&͘ ͘ŚĂƵĚŚƌǇ͕ :͘'͘ũĂĂůŝĞ͕
&͘ &ŽŶŶƵŵ͕K͘W͘KƩĞƌƐĞŶ͕:͘^ƚŽƌŵͲDĂƚŚŝƐĞŶ͕^ǇŶĂƉƟĐǀĞƐŝĐƵůĂƌ
ůŽĐĂůŝǌĂƟŽŶĂŶĚĞǆŽĐǇƚŽƐŝƐŽĨ>ͲĂƐƉĂƌƚĂƚĞŝŶĞǆĐŝƚĂƚŽƌǇŶĞƌǀĞ
ƚĞƌŵŝŶĂůƐ͗ĂƋƵĂŶƟƚĂƟǀĞŝŵŵƵŶŽŐŽůĚĂŶĂůǇƐŝƐŝŶƌĂƚŚŝƉƉŽĐͲ
ĂŵƉƵƐ͕:͘EĞƵƌŽƐĐŝ͘ϭϴ;ϭϵϵϴͿϲϬϱϵͲϲϬϳϬ͘
 ΀ϭϯ΁ s͘'ƵŶĚĞƌƐĞŶ͕&͘ &ŽŶŶƵŵ͕K͘W͘KƩĞƌƐĞŶ͕
:͘^ƚŽƌŵͲDĂƚŚŝƐĞŶ͕ZĞĚŝƐƚƌŝďƵƟŽŶŽĨŶĞƵƌŽĂĐƟǀĞĂŵŝŶŽĂĐŝĚƐ
ŝŶŚŝƉƉŽĐĂŵƉƵƐĂŶĚƐƚƌŝĂƚƵŵĚƵƌŝŶŐŚǇƉŽŐůǇĐĞŵŝĂ͗ĂƋƵĂŶƟƚĂͲ
ƟǀĞŝŵŵƵŶŽŐŽůĚƐƚƵĚǇ͕ :͘ĞƌĞď͘ůŽŽĚ&ůŽǁDĞƚĂďϮϭ;ϮϬϬϭͿ
ϰϭͲϱϭ͘
 ΀ϭϰ΁ s͘'ƵŶĚĞƌƐĞŶ͕ d͘͘ ,ŽůƚĞŶ͕:͘^ƚŽƌŵͲDĂƚŚŝƐĞŶ͕
'ĞƌŐŝĐƐǇŶĂƉƐĞƐŝŶŚŝƉƉŽĐĂŵƉƵƐĞǆŽĐǇƚŽƐĞĂƐƉĂƌƚĂƚĞŽŶ
ƚŽEDƌĞĐĞƉƚŽƌƐ͗ƋƵĂŶƟƚĂƟǀĞŝŵŵƵŶŽŐŽůĚĞǀŝĚĞŶĐĞĨŽƌĐŽͲ
ƚƌĂŶƐŵŝƐƐŝŽŶ͕DŽů͘ĞůůEĞƵƌŽƐĐŝ͘Ϯϲ;ϮϬϬϰͿϭϱϲͲϭϲϱ͘
 ΀ϭϱ΁ ͘,ĂƐƐĞů͕,͘ĂĐŚĞůĂƌĚ͕W͘ :ŽŶĞƐ͕&͘ &ŽŶŶƵŵ͕
h͘^ŽŶŶĞǁĂůĚ͕dƌĂĸĐŬŝŶŐŽĨĂŵŝŶŽĂĐŝĚƐďĞƚǁĞĞŶŶĞƵƌŽŶƐĂŶĚ
ŐůŝĂŝŶǀŝǀŽ͘īĞĐƚƐŽĨŝŶŚŝďŝƟŽŶŽĨŐůŝĂůŵĞƚĂďŽůŝƐŵďǇŇƵŽƌŽͲ
ĂĐĞƚĂƚĞ͕:͘ĞƌĞď͘ůŽŽĚ&ůŽǁDĞƚĂďϭϳ;ϭϵϵϳͿϭϮϯϬͲϭϮϯϴ͘
 ΀ϭϲ΁ z͘ ,Ğ͕W͘ Z͘,ŽĨ͕ t͘'͘:ĂŶƐƐĞŶ͕:͘͘ZŽƚŚƐƚĞŝŶ͕
:͘,͘DŽƌƌŝƐŽŶ͕ŝīĞƌĞŶƟĂůƐǇŶĂƉƟĐůŽĐĂůŝǌĂƟŽŶŽĨ'ůƵZϮĂŶĚ
ϭŝŶƚŚĞŵĂĐĂƋƵĞŵŽŶŬĞǇĞŶƚŽƌŚŝŶĂůĐŽƌƚĞǆ͗ĂƉŽƐƚĞŵͲ
ďĞĚĚŝŶŐŝŵŵƵŶŽŐŽůĚƐƚƵĚǇ͕ EĞƵƌŽƐĐŝ͘>ĞƩ͘ϯϭϭ;ϮϬϬϭͿϭϲϭͲ
ϭϲϰ͘
 ΀ϭϳ΁ D͘,ŝƌĂŵĂƚƐƵ͕/͘<ŝŶŶŽ͕<͘<ĂŶĂŬƵƌĂ͕<͘^ĂƚŽ͕
͘DŽƌŝ͕/ŶĐƌĞĂƐĞĚĂƐƉĂƌƚĂƚĞƌĞůĞĂƐĞĨƌŽŵďƌĂŝŶƐůŝĐĞƐŽĨĞƉŝůĞƉͲ
ƟĐĞǆƉĞƌŝŵĞŶƚĂůĂŶŝŵĂůƐĂŶĚĞīĞĐƚŽĨǀĂůƉƌŽĂƚĞŽŶŝƚ͕:ƉŶ͘:͘
WƐǇĐŚŝĂƚƌǇEĞƵƌŽů͘ϰϲ;ϭϵϵϮͿϱϰϭͲϱϰϯ͘
 ΀ϭϴ΁  d͘͘ ,ŽůƚĞŶ͕E͘͘ĂŶďŽůƚ͕<͘^ŚŝŵĂŵŽƚŽ͕
s͘'ƵŶĚĞƌƐĞŶ͕>ŽǁͲĂĸŶŝƚǇĞǆĐŝƚĂƚŽƌǇĂŵŝŶŽĂĐŝĚƵƉƚĂŬĞŝŶ
ŚŝƉƉŽĐĂŵƉĂůĂƐƚƌŽĐǇƚĞƐ͗ĂƉŽƐƐŝďůĞƌŽůĞŽĨEĂнͬĚŝĐĂƌďŽǆǇůĂƚĞ
ĐŽƚƌĂŶƐƉŽƌƚĞƌƐ͕'ůŝĂϱϲ;ϮϬϬϴͿϵϵϬͲϵϵϳ͘
 ΀ϭϵ΁  d͘͘ ,ŽůƚĞŶ͕s͘'ƵŶĚĞƌƐĞŶ͕'ůƵƚĂŵŝŶĞĂƐĂ
ƉƌĞĐƵƌƐŽƌĨŽƌƚƌĂŶƐŵŝƩĞƌŐůƵƚĂŵĂƚĞ͕ĂƐƉĂƌƚĂƚĞĂŶĚ'ŝŶ
ƚŚĞĐĞƌĞďĞůůƵŵ͗ĂƌŽůĞĨŽƌƉŚŽƐƉŚĂƚĞͲĂĐƟǀĂƚĞĚŐůƵƚĂŵŝŶĂƐĞ͕:͘
EĞƵƌŽĐŚĞŵ͘ϭϬϰ;ϮϬϬϴͿϭϬϯϮͲϭϬϰϮ͘
 ΀ϮϬ΁ ͘h͘:ŽŚĂŶŶĞƐƐĞŶ͕͘WĞƚĞƌƐĞŶ͕&͘ &ŽŶŶƵŵ͕
͘,ĂƐƐĞů͕dŚĞĂĐƵƚĞĞīĞĐƚŽĨǀĂůƉƌŽĂƚĞŽŶĐĞƌĞďƌĂůĞŶĞƌŐǇ
ŵĞƚĂďŽůŝƐŵŝŶŵŝĐĞ͕ƉŝůĞƉƐǇZĞƐ͘ϰϳ;ϮϬϬϭͿϮϰϳͲϮϱϲ͘
 ΀Ϯϭ΁ ͘h͘:ŽŚĂŶŶĞƐƐĞŶ͕,͘YƵ͕h͘^ŽŶŶĞǁĂůĚ͕
͘,ĂƐƐĞů͕&͘ &ŽŶŶƵŵ͕ƐƟŵĂƟŽŶŽĨĂƐƉĂƌƚĂƚĞƐǇŶƚŚĞƐŝƐŝŶ
'ĞƌŐŝĐŶĞƵƌŽŶƐŝŶŵŝĐĞďǇϭϯEDZƐƉĞĐƚƌŽƐĐŽƉǇ͕ EĞƵͲ
ƌŽƌĞƉŽƌƚϭϮ;ϮϬϬϭͿϯϳϮϵͲϯϳϯϮ͘
 ΀ϮϮ΁ <͘<ƵŬŝŶŽ͕d͘ ĞŐƵĐŚŝ͕īĞĐƚƐŽĨƐŽĚŝƵŵĚŝƉƌŽͲ
ƉǇůĂĐĞƚĂƚĞŽŶŐĂŵŵĂͲĂŵŝŶŽďƵƚǇƌŝĐĂĐŝĚĂŶĚďŝŽŐĞŶŝĐĂŵŝŶĞƐ
ŝŶƌĂƚďƌĂŝŶ͕ŚĞŵ͘WŚĂƌŵ͘Ƶůů͘;dŽŬǇŽͿϮϱ;ϭϵϳϳͿϮϮϱϳͲϮϮϲϮ͘
 ΀Ϯϯ΁ :͘͘>Ăŝ͕:͘D͘tĂůƐŚ͕^͘͘ĞŶŶŝƐ͕:͘͘ůĂƌŬ͕^ǇŶͲ
ĂƉƟĐĂŶĚŶŽŶͲƐǇŶĂƉƟĐŵŝƚŽĐŚŽŶĚƌŝĂĨƌŽŵƌĂƚďƌĂŝŶ͗ŝƐŽůĂƟŽŶ
ĂŶĚĐŚĂƌĂĐƚĞƌŝǌĂƟŽŶ͕:͘EĞƵƌŽĐŚĞŵ͘Ϯϴ;ϭϵϳϳͿϲϮϱͲϲϯϭ͘
 ΀Ϯϰ΁ D͘>ĂƌƐƐŽŶ͕:͘ƌŽŵĂŶ͕ŝīĞƌĞŶƚďĂƐĂůůĞǀĞůƐ
ŽĨĂD<//ƉŚŽƐƉŚŽƌǇůĂƚĞĚĂƚdŚƌϮϴϲͬϮϴϳĂƚŶŽĐŝĐĞƉƟǀĞĂŶĚ
ůŽǁͲƚŚƌĞƐŚŽůĚƉƌŝŵĂƌǇĂīĞƌĞŶƚƐǇŶĂƉƐĞƐ͕Ƶƌ͘ :͘EĞƵƌŽƐĐŝ͘Ϯϭ
;ϮϬϬϱͿϮϰϰϱͲϮϰϱϴ͘
 ΀Ϯϱ΁ ͘W͘ >ŝ͕y z͘͘ ŚĂŶŐ͕y͘>Ƶ͕D͘<͘ŚŽŶŐ͕z͘ ,͘:ŝ͕ǇͲ
ŶĂŵŝĐƌĞůĞĂƐĞŽĨĂŵŝŶŽĂĐŝĚƚƌĂŶƐŵŝƩĞƌƐŝŶĚƵĐĞĚďǇǀĂůƉƌŽĂƚĞ
ŝŶWdͲŬŝŶĚůĞĚĞƉŝůĞƉƟĐƌĂƚŚŝƉƉŽĐĂŵƉƵƐ͕EĞƵƌŽĐŚĞŵ͘/Ŷƚ͘ϰϰ
;ϮϬϬϰͿϮϲϯͲϮϳϬ͘
 ΀Ϯϲ΁ t͘>ŽƐĐŚĞƌ͕ /ŶǀŝǀŽĂĚŵŝŶŝƐƚƌĂƟŽŶŽĨǀĂůͲ
ƉƌŽĂƚĞƌĞĚƵĐĞƐƚŚĞŶĞƌǀĞƚĞƌŵŝŶĂů;ƐǇŶĂƉƚŽƐŽŵĂůͿĂĐƟǀŝƚǇŽĨ
'ĂŵŝŶŽƚƌĂŶƐĨĞƌĂƐĞŝŶĚŝƐĐƌĞƚĞďƌĂŝŶĂƌĞĂƐŽĨƌĂƚƐ͕EĞƵƌŽͲ
ƐĐŝ͘>ĞƩ͘ϭϲϬ;ϭϵϵϯͿϭϳϳͲϭϴϬ͘

΀ϯϭ΁Z͘>͘DĂĐĚŽŶĂůĚ͕D͘:͘DĐ>ĞĂŶ͕ŶƟĐŽŶǀƵůƐĂŶƚĚƌƵŐƐ͗
ŵĞĐŚĂŶŝƐŵƐŽĨĂĐƟŽŶ͕Ěǀ͘ EĞƵƌŽů͘ϰϰ;ϭϵϴϲͿϳϭϯͲϳϯϲ͘
 
΀ϯϮ΁͘DŽŶƟ͕͘WŽůĂǌǌŝ͕͘ŽŶƚĞƐƚĂďŝůĞ͕ŝŽĐŚĞŵŝĐĂů͕ŵŽůĞĐƵůĂƌ
ĂŶĚĞƉŝŐĞŶĞƟĐŵĞĐŚĂŶŝƐŵƐŽĨǀĂůƉƌŽŝĐĂĐŝĚŶĞƵƌŽƉƌŽƚĞĐƟŽŶ͕
Ƶƌƌ͘ DŽů͘WŚĂƌŵĂĐŽů͘Ϯ;ϮϬϬϵͿϵϱͲϭϬϵ͘
 
΀ϯϯ΁͘DŽƌůĂŶĚ͕<͘͘ŽůĚŝŶŐŚ͕͘'͘/ǀĞƌƐĞŶ͕͘,ĂƐƐĞů͕sĂůƉƌŽĂƚĞ
ŝƐŶĞƵƌŽƉƌŽƚĞĐƟǀĞĂŐĂŝŶƐƚŵĂůŽŶĂƚĞƚŽǆŝĐŝƚǇŝŶƌĂƚƐƚƌŝĂƚƵŵ͗
ĂŶĂƐƐŽĐŝĂƟŽŶǁŝƚŚĂƵŐŵĞŶƚĂƟŽŶŽĨŚŝŐŚͲĂĸŶŝƚǇŐůƵƚĂŵĂƚĞ
ƵƉƚĂŬĞ͕:͘ĞƌĞď͘ůŽŽĚ&ůŽǁDĞƚĂďϮϰ;ϮϬϬϰͿϭϮϮϲͲϭϮϯϰ͘
 
΀ϯϰ΁͘DŽƌůĂŶĚ͕^͘,ĞŶũƵŵ͕͘'͘/ǀĞƌƐĞŶ͕<͘<͘^ŬƌĞĚĞ͕͘,ĂƐƐĞů͕
ǀŝĚĞŶĐĞĨŽƌĂŚŝŐŚĞƌŐůǇĐŽůǇƟĐƚŚĂŶŽǆŝĚĂƟǀĞŵĞƚĂďŽůŝĐĂĐƟǀͲ
ŝƚǇŝŶǁŚŝƚĞŵĂƩĞƌŽĨƌĂƚďƌĂŝŶ͕EĞƵƌŽĐŚĞŵ͘/Ŷƚ͘ϱϬ;ϮϬϬϳͿ
ϳϬϯͲϳϬϵ͘
 
΀ϯϱ΁:͘s͘ EĂĚůĞƌ͕ ƐƉĂƌƚĂƚĞƌĞůĞĂƐĞĂŶĚƐŝŐŶĂůůŝŶŐŝŶƚŚĞŚŝƉƉŽĐͲ
ĂŵƉƵƐ͕EĞƵƌŽĐŚĞŵ͘ZĞƐ͘ϯϲ;ϮϬϭϭͿϲϲϴͲϲϳϲ͘
 
΀ϯϲ΁K͘W͘KƩĞƌƐĞŶ͕WŽƐƚĞŵďĞĚĚŝŶŐůŝŐŚƚͲĂŶĚĞůĞĐƚƌŽŶŵŝĐƌŽͲ
ƐĐŽƉŝĐŝŵŵƵŶŽĐǇƚŽĐŚĞŵŝƐƚƌǇŽĨĂŵŝŶŽĂĐŝĚƐ͗ĚĞƐĐƌŝƉƟŽŶŽĨĂ
ŶĞǁŵŽĚĞůƐǇƐƚĞŵĂůůŽǁŝŶŐŝĚĞŶƟĐĂůĐŽŶĚŝƟŽŶƐĨŽƌƐƉĞĐŝĮĐŝƚǇ
ƚĞƐƟŶŐĂŶĚƟƐƐƵĞƉƌŽĐĞƐƐŝŶŐ͕ǆƉ͘ƌĂŝŶZĞƐ͘ϲϵ;ϭϵϴϳͿϭϲϳͲ
ϭϳϰ͘

΀ϯϳ΁K͘W͘KƩĞƌƐĞŶ͕E͘ŚĂŶŐ͕&͘tĂůďĞƌŐ͕DĞƚĂďŽůŝĐĐŽŵƉĂƌƚͲ
ŵĞŶƚĂƟŽŶŽĨŐůƵƚĂŵĂƚĞĂŶĚŐůƵƚĂŵŝŶĞ͗ŵŽƌƉŚŽůŽŐŝĐĂůĞǀŝͲ
ĚĞŶĐĞŽďƚĂŝŶĞĚďǇƋƵĂŶƟƚĂƟǀĞŝŵŵƵŶŽĐǇƚŽĐŚĞŵŝƐƚƌǇŝŶƌĂƚ
ĐĞƌĞďĞůůƵŵ͕EĞƵƌŽƐĐŝĞŶĐĞϰϲ;ϭϵϵϮͿϱϭϵͲϱϯϰ͘
 
΀ϯϴ΁'͘ZŽƐĞŶďĞƌŐ͕dŚĞŵĞĐŚĂŶŝƐŵƐŽĨĂĐƟŽŶŽĨǀĂůƉƌŽĂƚĞ
ŝŶŶĞƵƌŽƉƐǇĐŚŝĂƚƌŝĐĚŝƐŽƌĚĞƌƐ͗ĐĂŶǁĞƐĞĞƚŚĞĨŽƌĞƐƚĨŽƌƚŚĞ
ƚƌĞĞƐ͍͕ĞůůDŽů͘>ŝĨĞ^Đŝ͘ϲϰ;ϮϬϬϳͿϮϬϵϬͲϮϭϬϯ͘
 
΀ϯϵ΁W͘ :͘^ĐŚĞĐŚƚĞƌ͕ z͘dƌĂŶŝĞƌ͕ :͘'ƌŽǀĞ͕īĞĐƚŽĨŶͲĚŝƉƌŽƉǇůĂĐĞƚĂƚĞ
ŽŶĂŵŝŶŽĂĐŝĚĐŽŶĐĞŶƚƌĂƟŽŶƐŝŶŵŽƵƐĞďƌĂŝŶ͗ĐŽƌƌĞůĂƟŽŶƐ
ǁŝƚŚĂŶƟͲĐŽŶǀƵůƐĂŶƚĂĐƟǀŝƚǇ͕ :͘EĞƵƌŽĐŚĞŵ͘ϯϭ;ϭϵϳϴͿϭϯϮϱͲ
ϭϯϮϳ͘
 
΀ϰϬ΁^͘D͘^ƚĂŚů͕ŶƟĐŽŶǀƵůƐĂŶƚƐĂƐŵŽŽĚƐƚĂďŝůŝǌĞƌƐĂŶĚ
ĂĚũƵŶĐƚƐƚŽĂŶƟƉƐǇĐŚŽƟĐƐ͗ǀĂůƉƌŽĂƚĞ͕ůĂŵŽƚƌŝŐŝŶĞ͕ĐĂƌͲ
ďĂŵĂǌĞƉŝŶĞ͕ĂŶĚŽǆĐĂƌďĂǌĞƉŝŶĞĂŶĚĂĐƟŽŶƐĂƚǀŽůƚĂŐĞͲŐĂƚĞĚ
ƐŽĚŝƵŵĐŚĂŶŶĞůƐ͕:͘ůŝŶ͘WƐǇĐŚŝĂƚƌǇϲϱ;ϮϬϬϰͿϳϯϴͲϳϯϵ͘
 
΀ϰϭ΁z͘dĂŬƵŵŝ͕͘DĂƚƐƵďĂƌĂ͕͘ZŝŶǀŝŬ͕K͘W͘KƩĞƌƐĞŶ͕dŚĞĂƌͲ
ƌĂŶŐĞŵĞŶƚŽĨŐůƵƚĂŵĂƚĞƌĞĐĞƉƚŽƌƐŝŶĞǆĐŝƚĂƚŽƌǇƐǇŶĂƉƐĞƐ͕ŶŶ͘
E͘z͘ ĐĂĚ͘^Đŝ͘ϴϲϴ;ϭϵϵϵͿϰϳϰͲϰϴϮ͘
 
΀ϰϮ΁E͘Z͘tŝůƐŽŶ͕:͘<ĂŶŐ͕͘s͘ ,ƵĞƐŬĞ͕d͘ >ĞƵŶŐ͕,͘sĂƌŽƋƵŝ͕
:͘'͘DƵƌŶŝĐŬ͕:͘͘ƌŝĐŬƐŽŶ͕'͘>ŝƵ͕WƌĞƐǇŶĂƉƟĐƌĞŐƵůĂƟŽŶŽĨ
ƋƵĂŶƚĂůƐŝǌĞďǇƚŚĞǀĞƐŝĐƵůĂƌŐůƵƚĂŵĂƚĞƚƌĂŶƐƉŽƌƚĞƌs'>hdϭ͕:͘
EĞƵƌŽƐĐŝ͘Ϯϱ;ϮϬϬϱͿϲϮϮϭͲϲϮϯϰ͘
IV

